 
16. Appendices  
16.[ADDRESS_808374] 2022 
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 1 of 70
C V N 4 2 4- 1 0 2; C A 3 8 7 3 6; 1 6. 1. 1 Pr ot oc ol a n d Pr ot oc ol A me n d me nts Pa ge 2 of 7 0 P P D 
P P D 
P P D er e v a 
N O T E T O FI L E 
T o: C er e v a n c e [ADDRESS_808375] er Fil e 
Fr o m: - C o n s ult a nt t o C er e v a n c e 
D at e: [ADDRESS_808376] u d y : C V N 4 2 4- 1 0 2 
R e: Pr o t o c ol Cl arifi c ati o n s 
T h e f oll o wi n g ar e cl a rifi c ati o n s f o r t h e C V N4 2 4 - 1 0 2 pr ot o c ol v er si o n 1. 0 d at e d 3 0 A u g 2 0 2 2 . 
•  9. 1. 5 Vit a l Si g n Pr o c e d ur e 
Si g n e d, 
Co n sult a nt 
Cer e va n c e o Cl arif yi n g t h a t r e s pir ati o n r at e i s n ot n e e d e d i n tri plt c at e 
o Cl arif yi n g t h at t h e tr i pli c at e m e a s ur e m e nt s at t h e "i niti a l p o st- d o s e " ti m e p oi nt ar e t o b e 
c oll e ct e d fr o m 1- [ADDRESS_808377] u g 
• S u b s e q u e nt p o st- d o s e m e a s ur e m e nt s (i. e ., 2 4 -, 4 8 -, 7 2 •, a n d 9 6 - h o ur s) ar e n o t 
n e e d e d i n tr ipli c at e 
 
N O T E  T O  FIL E  
 
 
T o: C er ev a nc e [ADDRESS_808378] er Fil e  
Fr o m:  , C o ns ult a nt t o C er ev a nc e  
D at e: [ADDRESS_808379] u dy: C V N 4 2 4 -1 0 2  
 
R e:  Pr ot oc ol Cl arific ati o ns  
 
 
T h e f oll o wi n g ar e  cl arific ati o ns f or t h e C V N [ADDRESS_808380] a w al 
of a P artici p a nt .  
 
Existi n g l a n g u a g e:  
If a p artici p a nt is n ot e d t o h a v e AL T or A S T el e v at e d > 3 × UL N o n [ADDRESS_808381] ors, cli nic al si g ns a n d sy m pt o ms, a n d r es ults of a ny a d diti o n al di a g n ostic t ests p erf or m e d.  
 
If a p artici p a nt is n ot e d t o h a v e AL T or A S T > 3 × UL N a n d t ot al bilir u bi n  > 2 × UL N f or w hic h a n 
alt er n ati v e eti ol o g y h as n ot b e e n i d e ntifi e d, t h e e v e nt s h o ul d b e r ec or d e d as a n S A E a n d r e p ort e d 
as p er S ecti o n 9. 7. 2.  T h e I nv esti g at or m ust c o nt act t h e M e dic al M o nit or t o disc uss t h e r el e v a nt 
p artici p a nt d et ails a n d p ossi bl e alt er n ati v e eti ol o gi es, s uc h as ac ut e vir al h e p atitis A or B or ot h er 
ac ut e li v er dis e as e or m e dic al hist ory/c o nc urr e nt m e dic al c o n diti o ns. F oll o w -u p l a b or at or y t ests will 
b e at t h e discr eti o n of t h e I nv esti g at or . 
 
T o b e r e pl ac e d wit h:  
If a p artici p a nt is n ot e d  t o h a v e AL T or A S T el e v at e d > 2 × UL N at a ny p oi nt, t h e a b n or m ality s h o ul d 
b e r ec or d e d as a n A E.  
 
If a p artici p a nt is n ot e d t o h a v e  
 Al a ni n e a mi n otr a nsf er as e ( AL T) or as p art at e a mi n otr a nsf er as e ( A S T) > 8 × u p p er li mit of 
n or m al ( UL N), or  
 AL T or A S T > 5 × UL N a n d p ersists f or m or e t h a n 2 w e eks, or  
 AL T or A S T > 3 × UL N i n c o nj u ncti o n wit h el e v at e d t ot al bilir u bi n > 2 × UL N or I N R > 1. 5, or  
 AL T or A S T > 3 × UL N wit h a p p e ar a nc e of f ati g u e, n a us e a, v o miti n g, ri g ht u p p er q u a dr a nt D o c u Si g n E n v el o p e I D: E 3 D 7 9 2 A 1- 2 3 B D- 4 A B 9- 9 2 C 4- 6 8 D 3 9 6 E 8 C 3 1 B 
C V N 4 2 4- 1 0 2; C A 3 8 7 3 6; 1 6. 1. 1 Pr ot oc ol a n d Pr ot oc ol A me n d me nts Pa ge 3 of 7 0 P P D 
 
p ai n or t e n d er n ess, f e v er, r as h a n d/ or e osi n o p hili a ( > 5 %)  
 
t h e e v e nt s h o ul d b e r ec or d e d as a n S A E ( n ot e t h e r e as o n f or S eri o us n ess: m e dic all y i m p ort a nt 
e v e nt) a n d r e p ort e d as p er S ecti o n 9. 7. 2.  T h e I nv esti g at or m ust r ef er t o s ecti o n 7. [ADDRESS_808382] e ps.  
 
  
Si g n e d,  
 
 
 
, M D  
C hi ef  M e dic al  Offic er  
C er ev a n c e  
 D o c u Si g n E n v el o p e I D: E 3 D 7 9 2 A 1- 2 3 B D- 4 A B 9- 9 2 C 4- 6 8 D 3 9 6 E 8 C 3 1 B 
1 0 / 2 6 / 2 0 2 2 
C V N 4 2 4- 1 0 2; C A 3 8 7 3 6; 1 6. 1. 1 Pr ot oc ol a n d Pr ot oc ol A me n d me nts Pa ge 4 of 7 0 P P D 
P P D 
 
N O T E  T O  FIL E  
 
T o: C er ev a nc e [ADDRESS_808383] er Fil e  
Fr o m:  , C o ns ult a nt t o C er ev a nc e  
D at e: [ADDRESS_808384] u dy: C V N 4 2 4 -1 0 2  
 
R e:  Pr ot oc ol Cl arific ati o ns  
 
T h e f oll o wi n g ar e cl arific ati o ns f or t h e C V N 4 2 4 -1 0 2 pr ot oc ol v ersi o n 1 . 0  d at e d 3 0 A u g 2 0 2 2.  
 
 R a n d o miz ati o n: cl arifyi n g t h at C el eri o n will s erv e as d esi g n e e f or t h e r a n d o miz ati o n g e n er ati o n  
 P hysic al Ass ess m e nt at f oll o w -u p visit: cl arifyi n g t h at t his is t o b e a s y m pt o m driv e n p hysic al 
ex a mi n ati o n  
 Vit al si g ns: cl arif yi n g t h at t e m p er at ur e is n ot n e e d e d i n tri plic at e  
 A p p e n dix A : Sc h e d ul e of St u dy Pr oc e d ur es  
o F oll o w -U p:  
 O v er all St u dy D a y # t o b e u p d at e t o 4 2  
o R a n d o miz ati o n : 
 T o b e m ov e d fr o m first C h ec k -i n t o first D osi n g d a y  
o Pr e g n a nc y T est:  
 A d d ass ess m e nt t o D ay 5 of P eri o d 3 
o C-S S R S:  
 R e m ov e ass ess m e nt fr o m D a y 1 of P eri o d s 2 a n d 3  as w ell as fr o m F oll o w -U p visit  
o P hysic al Ex a mi n ati o n:  
 A d d ass ess m e nt t o D ay [ADDRESS_808385] -d os e  
o Vit al Si g ns (f o ot n ot e 3):  
 U p d at e  t o i ncl u d e R es pir ati o ns  
 R es pir ati o ns s h o ul d als o b e a d d e d t o t h e St u dy S u m m ar y ( p a g e 1 1)  
o Uri n al ysis (f o ot n ot e 5)  
 U p d at e t o i ncl u d e st at e m e nt t h at  Pr e d os e l a bs d o n ot n e e d t o b e r evi e w e d pri or t o 
d osi n g  
o Cli nic al l a b or at ory t ests  (f o ot n ot e 7):  
 Parti al list s h o ul d b e r e m o v e d as T a bl e [ADDRESS_808386] of t ests  
o E C G  (f o ot n ot e 1 1 ):  
 St u dy d a ys t o b e u p d at e d t o 0, 1 4, a n d 2 8  
 [ADDRESS_808387] -d os e wi n d o w t o b e u p d at e d t o  +/ - 3 0 mi n ut es  
  
Si g n e d,  
 
 
 
 M D  
C hi ef  M e dic al  Offic er  
C er ev a n c e  
 D o c u Si g n E n v el o p e I D: 1 7 C 7 A 5 1 8- E 9 6 A- 4 7 B 9- B 5 7 4- 6 9 6 2 6 2 8 2 A 1 3 4 
C V N 4 2 4- 1 0 2; C A 3 8 7 3 6; [ADDRESS_808388] of Food on the Tablet Formulation in Healthy Adult Volunteers  
Short Title: Relative Bioavailability and Food Effect Study of CVN424 
Sponsor:  Cerevance Beta, Inc. 
One Marina Park Drive , Suite 1410 
[LOCATION_011], MA [ZIP_CODE] 
Study Number:  CVN424 -102 
IND Number:  [ADDRESS_808389] Number:   Not Applicable  
Compound:  CVN424  
Version : 
Date:  Protocol 1.[ADDRESS_808390] 2022 
CONFIDENTIAL PROPERTY O
F CEREVANCE  
This document is a CONFIDENTIAL  communication of Cerevance Beta, Inc. (“Cerevance”). Acceptance of this 
document constitutes the agreement by [CONTACT_1955][INVESTIGATOR_609737]. Furthermore, the information is only meant for review and compliance by [CONTACT_1955][INVESTIGATOR_841], his or her staff, and applicable institutional review committee and regulatory agencies to enable conduct of the study.  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808391] T y pe / R ole  C o nt act  
Seri o us a d verse e ve nts  a n d pre g na nc y re p orti n g  Celeri o n  
Me dical M o nit or  
(carries o verall res p o nsi bilit y f or t he c o n d uct of t he 
st u d y )  Pr o P har ma Re prese ntati ve  
Res p o nsi ble Me dical Officer  
(me dical a d vice o n pr ot oc ol  a n d  c o m p o u n d )  M . D. 
E ma il: D o c u Si g n E n v el o p e I D: 7 4 E 0 8 A 9 2- D 5 4 4- 4 5 C F- B 8 6 8- 7 5 1 D F 4 A 7 4 1 5 A 
C V N 4 2 4- 1 0 2; C A 3 8 7 3 6; [ADDRESS_808392] u d y pr ot oc ol a n d als o i n acc or d a nce wit h t he 
f oll o wi n g: 
• T he et hical pri nci ples t h at ha ve t heir ori gi n i n t he Declar ati o n  of Helsi n ki. 
• I nter nati o nal C o u ncil o n Har m o nisati o n (I C H)  E 6 [ R 2]  G o o d Cli nical Practice ( G C P) : 
I nte grate d A d de n d u m t o E 6[ R 1] . 
• All a p plica ble la ws a n d r e g ulati o ns, i ncl u di n g, wit h o ut li mitati o n, data pri vac y la ws, cli nical 
trial discl os ure la ws, a n d re g ulati o ns. 
 
 
SI G N A T U R E S  
A p pr o ve d b y: 
 
 
 
Si g nat ure _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _        Date _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 M. D.  
Res p o nsi ble Me dical Officer  
Cere va n ce, I n c.   D o c u Si g n E n v el o p e I D: 7 4 E 0 8 A 9 2- D 5 4 4- 4 5 C F- B 8 6 8- 7 5 1 D F 4 A 7 4 1 5 A 
C V N 4 2 4- 1 0 2; C A 3 8 7 3 6; [ADDRESS_808393] read and that I understand this protocol, the Investigator’s Brochure, and 
any other product information provided by [CONTACT_456]. I agree to conduct this study in accordance with the requirements of this protocol and also to protect the rights, safety, privacy, and well -being of study participants  in accordance with the following: 
• The ethical principles that have their origin in the Declaration of Helsinki  
• International Council on Harmonisation, E6 [R2]; GCP  Integrated Addendum to E6 [R1] 
• All applicable laws and regulations, including, without limitation, data privacy laws and regulations 
• Regulatory requirements for reporting serious adverse events (SAE s) defined in Section 9.7 
of this protocol 
• Terms outlined in the Clinical Study Site Agreement 
• Appendix B – R esponsibilities of the Investigator 
 
 I further authorize that my personal information may be processed and transferred in accordance 
with the uses contemplated in Ap pendix C of  this protocol. 
 
  
Signature [CONTACT_185717] (print or type)   
  
Investigator’s Title   
  
Location of Facility (City, State/Prov ince)  
  
Location of Facility (Country)   
 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808394] of Abbreviations ...................................................................................................13  
4.0 INTRODUCTION  .............................................................................................................15  
4.1 Background ..................................................................................................................15  
4.2 Rationale for the Proposed Study ................................................................................19  
5.0 STUDY OBJECTIVES AND ENDPOINTS  .....................................................................20  
5.1 Objectives  ....................................................................................................................20  
6.0 STUDY DESIGN AND DESCRIPTION  ..........................................................................21  
6.1 Study Design ................................................................................................................21  
6.2 Justification for Study Design, Dose, and Endpoints ..................................................22  
6.3 Premature Termination or Suspension of Study or Investigational Site ......................22  
6.3.1  Criteria for Premature Termination or Suspension of the Study ...........................22  
6.3.2  Criteria  for Premature Termination or Suspension of Investigational Sites ..........22  
6.3.3  Procedures for Premature Termination or Suspension of the Study or the 
Participation of Investigational Site(s) ...................................................................22  
7.0 PARTICIPANT POPULATION  .......................................................................................23  
7.1 Inclusion Criteria  .........................................................................................................23  
7.2 Exclusion Criteria  ........................................................................................................23  
7.3 Diet, Fluid, and Activity Control .................................................................................26  
7.3.1  On Dosing Days: ....................................................................................................26  
7.4 Criteria for Discontinuation or Withdrawal of a Participant .......................................27  
7.5 Procedures for Discontinuation or Withdrawal of a Participant ..................................28  
8.0 CLINICAL TRIAL MATER IAL MANAGEMENT  .........................................................29  
8.1 Study Medication and Materials ..................................................................................29  
8.1.1  Dosage Form, Manufacturing, Packaging, and Labeling ......................................29  
8.1.2  Drug Storage ..........................................................................................................29  
8.1.3  Dose  and Regimen  .................................................................................................30  
8.1.4  Overdose ................................................................................................................30  
8.2 Investigational Drug Assignment and Dispensing Procedures ....................................31  
8.3 Randomization Code Creation and Storage .................................................................31  
8.4 Accountability and Destruction of Sponsor-Supplied Drugs.......................................31  
9.0 STUDY PLAN  ...................................................................................................................33  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 10 of 70
CVN424   
Study No. CVN424 -102 Page 6 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
9.1 Study Procedures .........................................................................................................33  
9.1.1  Informed Consent Procedure .................................................................................33  
9.1.2  Demographics, Medical History, and Medication History Procedure ...................33  
9.1.3  Physical Exami nation Procedure ...........................................................................33  
9.1.4  Weight, Height, and BMI.......................................................................................33  
9.1.5  Vital Sign Procedure ..............................................................................................34  
9.1.6  Documentation of Concomitant Medications ........................................................34  
9.1.7  Documentation of Concurrent Medical Conditions ...............................................34  
9.1.8  ECG Procedure ......................................................................................................34  
9.1.9  PK Sample Collection  ............................................................................................35  
9.1.10  PK Parameters  ........................................................................................................35  
9.1.11  Procedures for Clinical Laboratory Samples .........................................................36  
9.1.12  Contraception and Pregnancy Avoidance Procedure .............................................37  
9.1.13  Pregnancy  ...............................................................................................................38  
9.1.14  Documentation of Screen Failure  ..........................................................................39  
9.1.15  Documentation of Randomization .........................................................................40  
9.2 Monitoring Participant Treatment Compliance  ...........................................................40  
9.3 Schedule of Observations and Procedures ...................................................................40  
9.3.1  Screening ................................................................................................................40  
9.3.2  Inpatient Check -In .................................................................................................40  
9.3.3  Dosing ....................................................................................................................40  
9.3.4  Washout and Discharge .........................................................................................40  
9.3.5  Final Visit (discharge day from clinic)  ..................................................................40  
9.3.6  Early Termination  ..................................................................................................41  
9.3.7  Follow-up Visit ......................................................................................................41  
9.4 Biological Sample Retention and Destruction  .............................................................41  
9.5 Blood Volume ..............................................................................................................41  
9.6 Definitions....................................................................................................................42  
9.6.1  AE ..........................................................................................................................42  
9.6.2  Additional Points to Consider for PTEs and AEs ..................................................42  
9.6.3  SAEs  ......................................................................................................................44  
9.6.4  Severity of AEs ......................................................................................................44  
9.6.5  Causality of AEs ....................................................................................................44  
9.6.6  Relationship to Study Procedures ..........................................................................45  
9.6.7  Start Date  ...............................................................................................................45  
9.6.8  Stop Date ................................................................................................................45  
9.6.9  Frequency  ...............................................................................................................45  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 11 of 70
CVN424   
Study No. CVN424 -102 Page 7 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
9.6.10  Action Concerning Study Medication ...................................................................45  
9.6.11  Outcome .................................................................................................................45  
9.7 Procedures  ....................................................................................................................46  
9.7.1  Collection and Reporting of AEs ...........................................................................46  
9.7.2  Collection and Reporting of SAEs .........................................................................47  
9.7.3  Reporting of Abnormal LFT ..................................................................................47  
9.8 Follow-up of SAEs ......................................................................................................47  
9.8.1  Safety Reporting to Investigators, IRBs, and Regulatory Authorities ...................48  
10.0  DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_1645]  ..............................................................49  
10.1  CRFs (Electronic)  ........................................................................................................[ADDRESS_808395] Retention  .........................................................................................................49  
11.0  STATISTICAL METHODS  ..............................................................................................51  
11.1  Statistical and Analytical Plans  ....................................................................................51  
11.1.1  Analysis Sets  ..........................................................................................................51  
11.1.2  Analysis of Demographics and Other Baseline Characteristics  ............................51  
11.1.3  PK Analysis  ...........................................................................................................51  
11.1.4  Safety Analysis  ......................................................................................................52  
11.2  Interim Analysis and Criteria for Early Termination  ...................................................52  
11.3  Determination of Sample Size  .....................................................................................53  
12.0  QUALITY CONTROL AND QUALITY ASSURANCE  .................................................54  
12.1  Study- Site Monitoring Visits  .......................................................................................54  
12.2  Protocol Deviations ......................................................................................................54  
12.3  Quality Assurance Audits and Regulatory Agency Inspections ..................................55  
13.0  ETHICAL ASPECTS OF THE STUDY  ...........................................................................56  
13.1  IRB Approval ...............................................................................................................56  
13.2  Participant Information, Informed Consent, and Participant Authorization ................56  
13.3  Participant Confidentiality  ...........................................................................................58  
13.4  Publication, Disclosure, and Clinical Trial Registration Policy  ..................................58  
13.4.1  Publication and Disclosure ....................................................................................58  
13.4.2  Clinical Trial Registration ......................................................................................59  
13.4.3  Clinical Trial Results Disclosure  ...........................................................................59  
13.5  Insurance and Compensation for Injury .......................................................................59  
14.0  REFERENCES  ..................................................................................................................60  
 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808396] OF A PPENDICES  
Appendix A:  Schedule of Study Procedures ...............................................................................61  
Appendix B:  Responsibilities of the Investigator  ........................................................................63  
Appendix C:  Investigator Consent to Use of Per sonal Information ............................................64  
 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 13 of 70
CVN424   
Study No. CVN424 -102 Page 9 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
2.0 STUDY SUMMARY  
Name [CONTACT_790](s):  
Cerevance Beta, Inc.  Compound:  
CVN424  
Title of Protocol:  A Randomized, Open -Label, Single Oral 
Dose, Three- Way Cross -Over Trial to Evaluate the Relative 
Bioavailability of CVN424 Suspension and Tablet Formulations 
Including an Assessment of the Effect of Food on the Tablet Formulation in Healthy Adult Volunteers  IND No.: [ADDRESS_808397] No.:  Not applicable  
Study Number:  CVN424 -102 Phase:  1 
Study Design:  
This is a Randomized, Open -Label, Single Oral Dose, Three- Way Cross -Over Trial to Evaluate the Relative 
Bioavailability of CVN424 Suspension and Tablet Formulations in Healthy Volunteers Under Fasted and Fed Conditions. The overall study design is outlined below:  
      
Sequence  Dosing #1 
(Period 1 Day 1)  Dosing #2  
(Period 2 Day 1)   Dosing #3  
(Period 3 Day 1)  
1 (n=5)  Suspension 
(fasted)  
W a s h o u t Tablet (fasted)  
W a s h o u t  Tablet (fed)  
   
2 (n=6)  Tablet (fasted)  Tablet (fed)  Suspension (fasted)  
   
3 (n=5)  Tablet (fed)  Suspension (fasted)  Tablet (fasted)  
   
4 (n=5)  Suspension 
(fasted)  Tablet (fed)  Tablet (fasted)  
    
5 (n=5)  Tablet (fasted)  Suspension (fasted)  Tablet (fed)  
   
6 (n=6)  Tablet (fed)  Tablet (fasted)  Suspension (fasted)  
     
 
32 healthy male or female participants will be enrolled in 1 of 6 sequences (designated as 1 through 6, respectively) in an ascending fashion. Sequences 1, 3, 4, and [ADDRESS_808398] 6 participants each.  
 
Each sequence will proceed through the three cross -overs (suspension- fasted, tablet -fed, and tablet -fasted) according to 
the schematic above, with dosing to occur on Days [ADDRESS_808399] of food on CVN424 bioavailability in t ablet formulation, the single dose will be administered after 
ingestion of a standardized high- fat, high- calorie meal according to FDA Guidance for Industry (Food -effect 
bioavailability and fed bioequivalence studies, Jun 2022).  
 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 14 of 70
CVN424   
Study No. CVN424 -102 Page 10 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
Participants for all sequ ences will be admitted to the study unit 1 day prior to dosing and remain in the unit for safety 
and pharmacokinetics (PK) assessments through [ADDRESS_808400] -dose. The total confinement period will be 5 nights for 
each period unless extended at the discreti on of the Investigator, e.g., for monitoring and/or management of adverse 
events (AEs).  
 
Once [ADDRESS_808401] -dose PK has been collected, participants will be discharged from the unit for the remainder of the 
washout period and return the day prior to their next scheduled dosing period.  
Primary  Objective:  
To determine the relative bioavailability of 150 milligrams (mg) of CVN424 administered in a single dose of 
suspension formulation compared to 150 mg tablet.  
Secondary  Objective s: 
To establish the effects of food on the rate and extent of absorption of CVN424 150 mg tablet when administered in fed 
conditions compared to administration under fasting conditions.  
To assess the tablet's safety under fast and fed conditions and suspension u nder fasted conditions.  
Exploratory Objectives:  
To explore serum/plasma (e.g., potential characterization of drug metabolites) that may contribute to variability in CVN424 . 
To assess urine concentrations and volumes to enable calculation of urine PK parameters where possible.  
Participant  Population:  
Healthy male and female participants 18 to 55 years old (inclusive)  
Number of Participants : 
Estimated total: 32 participants  
(4 sequences of 5 and 2 sequences of 6)  Number of Sites:  
1 ([LOCATION_002])  
Dose Level(s):  
Participants to receive a single -dose level of 150 mg CVN424 in 
either tablet or suspension formulation  Route of Administration:  
Oral 
 
Duration of Treatment:  
Single oral dose on Day 1 of Periods 1, 2, & 3 (Study Days 0, 14, & 28)  Period of Evaluation:  
• Screening  Period: up to 28 days 
• [ADDRESS_808402] -dose blood draw on 
Day 5  
• 9 additional days of washout (Days 6- 13) 
• To be repeated for the subsequent two Periods  
• Total Duration: Approximately 10 weeks  
Main Criteria for Inclusion:  
Healthy male and female participants, [ADDRESS_808403] a body mass index (BMI) between 18.0 and 35 kg/m
[ADDRESS_808404] of inclusion criteria is provided in Section 7.1. 
Main Criteria for Exclusion:  
Participants are vegan, vegetarian, lactose intolerant, or follow a Kosher diet. Participants have a known hypersensitivity to any component of the formulation of CVN424. Participants have evidence of clinically significant 
[CS] neurologic, cardiovascular,  
pulmonary, hepatic, hematopoietic disease, renal, metabolic, gastrointestinal, urologic, 
immunologic, endocrine disease, serious allergy, allergic skin rash, psychiatric disorder, or other abnormality that may 
impact the ability of the participant to participate or potentially confound the study results. Any finding in the 
participant’s medical history, physical examination, or safety laboratory tests gives reasonable suspi[INVESTIGATOR_1884] a condition 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808405] of exclusion criteria is provided in Section 7.2.  
In addition, participants may not use any excluded medications, supplements, or food products. Concomitant 
medications and dietary products to be excluded are listed in  Table 2. 
 
Main Criteria for Evaluation and Analyses:  
- Safety  assessments:  
Safety parameters will be collected from the signing of the informed consent form (ICF) until final charge and include 
AEs, clinical laboratory results, vital signs, physical examinations, and electrocardiogram (ECG).  
• Vital signs will include body temperature measurement, blood pressure, and heart rate (beats per minute [bpm]).  
• Orthostatic vital signs (blood pressure and heart rate) will be recorded  
• Standard 12- lead ECG will be recorded. Clinical laboratory data collec
ted will include hematology, chemistry, 
and urinalysis.  
• Physical exams  
A complete list of safety assessments is provided in Section 9.1, and the full Schedule of Study Procedures  is provided 
in Appendix A. 
 
- PK: 
Plasma PK parameters will  be used to determine the relative bioavailability of CVN424 suspension to tablet.  
Plasma and urine samples will be collected for the determination of concentrations of CVN424 throughout the study as 
prescribed in the Schedule of Assessments ( Appendix A).  
PK parameters of CVN424 will be derived using noncompartmental analysis methods from the concentration- time data 
for all evaluable participants. Actual sampling times, rather than scheduled sampling times, will be used in all computations involving sampling times. The following PK parameters will be determined from concentrations of CVN424 in plasma: maximum observed plasma concentration (C
max), time to reach C max (Tmax), time taken for drug to 
appear in systemic circulation following administration (T lag), area under plasma concentration -time curve (AUC) from 
time [ADDRESS_808406] quantifiable concentration (AUC 0-t), and truncated AUC from time 0 to 96 hours (AUC 0- 96h), AUCinf, 
terminal elimination half -life (t 1/2), apparent clearance after extravascular administration (CL/F), apparent volume of 
distribution after extravascular administration (V z/F) where possible  
 
- Endpoints:   
The primary endpoints of this study will be the following: the relative bioavailability of the CVN424 solution and 
CVN424 tablet formulation in the fasted state based on Cmax, Tmax, AUC inf, and AUC 0- 96h. 
Additionally, the ratio of the PK parameters between CVN424 solution and tablet in the fasted state will be calculated 
and summarized descriptively. An analysis of variance (ANOVA) on log- transformed PK parameters (AUC 0-t, AUC 0- 
96, Cmax) will be performed. Ratios of geometric means and 90% confidence intervals will be calculated. T max will be 
compared between the CVN424 solution and the CVN424 tablet.  
The secondary endpoints will be the following: The ratio of the PK parameters between CVN424 tablets in the fed and fasted state will be calculated and summarized descriptively. In addition, an ANOVA  on log- transformed PK 
parameters (AUC0 -t, AUC0 - 96h, Cmax) will be performed. Ratios of geometric means and 90% confidence intervals 
will be calculated. Tmax will be compared between CVN424 tablets in the fed and fasted state.  
The additional endpoints may include the following plasma PK parameters of CVN424: AUC∞ and t1/2z  
Exploratory endpoints may include characterization of metabolic enzyme and transporter polymorphisms and/or qualitative metabolite identification in plasma and/or urine. Exploratory endp oints may also include renal PK 
parameters; cumulative amount of unchanged drug excreted into the urine (Ae), fraction of unchanged drug excreted in 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 16 of 70
CVN424   
Study No. CVN424 -102 Page 12 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
the urine (fe), and renal clearance (CL R). 
Safety assessments will be measured by [CONTACT_3148] -emergent advers e events (TEAEs), and tolerability will be measured 
by [CONTACT_609752] (D/C) due to AE.  
Statistical Considerations:  
The proportion of participants administered CVN424 in tablet formulation who achieved at least an 80 percent relative 
bioavailability compared to CVN424 administered in suspension formulation as calculated by [CONTACT_609753]- time curves (AUC - area under the curve). 
 
Safety:  
AEs will be presented in listings, and TEAEs will be summarized. Individua l results of laboratory tests (hematology, 
chemistry, and urinalysis) will be recorded at baseline and post -dose, and changes from baseline will be summarized 
using shift tables. Individual vital signs will be recorded and observed values and changes from baseline will be 
summarized. Individual results of quantitative ECG parameters from the 12- lead safety ECGs will be listed and 
observed values and changes from baseline will be summarized. All summaries will be performed by [CONTACT_609754] 
(suspension and table fasted and tablet fed separately), and CVN424 suspension versus tablet overall, and separately 
each of the 6 CVN424 sequences overall. Physical exam findings will be presented in data listings.  
 
PK Analysis : 
Noncompartmental pharmacokinetic (PK) calcul ations include C max, Tmax, and AUC 0-96h active ingredients.  
Sample Size Justification:   
It is planned to enroll 32 male or female participants for participation. Based on previous PK studies with CVN424, it 
was determined 28 participants would be needed to show bioequivalence, assuming an intra -participant CV of 16% and 
an expected ratio of 1:10. [ADDRESS_808407] 28 evaluable participants.  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808408]  aspartate aminotransferase  
AUC  area under the plasma concentration -time curve  
AUC ∞ area under the plasma concentration -time curve from time [ADDRESS_808409] 
quantifiable concentration  
BDI  Beck Depression Inventory  
BMI  
bpm 
CGI  body mass index  
beats per minute  
Clinical Global Impression Scale   
CL/F  apparent clearance after extravascular administration  
CL R renal clearance  
Cmax maximum observed plasma concentration  
Cmin minimum observed plasma concentration  
CNS  
COMT  
CRP  
CRU  central nervous system  
catechol -O-methyl transferase  
c-reactive protein  
clinical research unit  
CS clinically significant  
CSF 
DBS  
D/C  cerebrospi[INVESTIGATOR_609738] -stimulating hormone  
GCP  Good Clinical Practice  
GGT  γ-glutamyl transferase  
HBsAg  hepatitis B surface antigen  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808410]  
MAO -B monoamine oxidase B  
MedDRA  Medical Dictionary for Regulatory Activities  
MSN  medium spi[INVESTIGATOR_609739]’s correction method  
QTcF  QT interval with Fridericia’s correction method  
RNA  ribonucleic acid  
SAE  serious adverse event  
SAP  statistical analysis plan  
SOC  system organ class  
S[LOCATION_003]Rs  suspected unexpected serious adverse reactions  
t1/2z terminal elimination half -life 
TEAE  
tlag treatment -emergent adverse event  
time taken for drug to appear in systemic circulation following 
administration  
tmax time to reach C max 
ULN  
UPDRS  upper limit of normal  
Unified Parkinson’s Disease Rating Scale  
Vz/F apparent volume of distribution after extravascular administration  
Vz/Fss apparent volume of distribution after extravascular administration at 
steady state  
WHO  
WOCBP  World Health Organization  
woman of childbearing potential  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 19 of 70
CVN424   
Study No. CVN424 -102 Page 15 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
4.0 INTRODUCTION 
4.1 Background 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder of the central nervous system 
(CNS) caused by [CONTACT_609755] (Wichmann, 2011). PD afflicts >1 million individuals in the 
[LOCATION_002] of America and >10 million worldwide (APDA parkinson .org, accessed 26 Jan 
2018), causing cardinal symptoms of tremor, bradykinesia, rigidity, and postural instability. Motor 
fluctuations refer to a decline in the usual benefit from levodopa and develop gradually after 
several years of successful treatment.  Most patients will eventually experience motor fluctuations 
as their disease progresses.   There are several types of motor fluctuations , including wearing off, 
morning off, partial on, delayed on, dose failure , and unpredictable off.  As PD progresses and 
there is a continuous loss of dopamine neurons, the peaks and troughs of the levodopa le vels 
become more problematic and result in motor fluctuations.  Changes in the gastrointestinal tract 
due to PD can slow the absorption of levodopa and, thus, the rate at which it reaches the brain , and 
this also contributes to motor fluctuations.  Current  treatment s for motor fluctuations include 
levodopa dose changes  and medications that delay the breakdown of dopamine, including 
catechol -O-methyl transferase (COMT) inhibitors and monoamine oxidase B (MAO -B) inhibitors. 
Dopamine agonists may also be prescribed.  Apomorphine rescue, levodopa gel delivered to the 
small intestine, and deep brain stimulation may also be employed (APDA parkinson.org, April 
2017). The financial burden of PD is significant.  
GPR6 is an orphan G -protein coupled receptor that is selectively expressed in the brain and is a 
nondopaminergic target for the treatment of PD. In the brain, GPR6 is predominantly localized to 
striatopallidal medium spi[INVESTIGATOR_174331] (MSNs) that also express dopamine D2 receptors (Lein et al. 
2007; also, Cerevance data on file). GPR6 is a constitutively active Gs -coupled receptor that 
functionally opposes the Gi-coupled D2 receptor in indirect MSNs. Pharmacological intervention 
to inhibit the GPR6 pathway using an inverse agonist is predicted to exert antiparkinsonian effects 
by [CONTACT_609756] D1- receptor -expressing MSNs of the direct (striatonigral) pathway. 
CVN424  is a potent and selective inverse agonist of GPR6. Two studies have been completed with 
CVN424 in human participants. 
A first -in-human safety study of CVN424 in 64 healthy volunteers has been completed 
([STUDY_ID_REMOVED]); the study findings are summarized in the Investigator’s Brochure. In brief, 
CVN424 was safe and well tolerated when administered to healthy participant s as a single oral 
dose of between 1 milligram ( mg) and 225 mg or when administered as 7 daily oral doses of 
between 25 mg and 150 mg. Study drug- related adverse events (AEs) were reported by 2 of 40 
participant s (5.0%) overall in the single -dose cohorts (feeling hot; headache). Study drug -related 
AEs were reported by 2 of 24 participant s (8.3%) overall in the multiple -dose cohorts (dysphagia; 
chills). With one exception, all A Es were mild in severity; dysphagia of moderate severity led to 
treatment discontinuation in one participant  after their third daily  dose (75 mg). There were no 
severe or serious A Es, and all A Es resolved by [CONTACT_2054]. Administration of the first 
dose of CVN424 was associated with an elevation in group mean and median body temperature. 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 20 of 70
CVN424   
Study No. CVN424 -102 Page 16 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
These changes were detectable at 1 hour (h) post- dose (the earliest scheduled post -dose 
assessment), increased further by [ADDRESS_808411] dose of CVN424, not 
following subsequent doses. No other trends in vital sign measurements were noted. No treatment -
related trends were observed in the clinical laboratory results or 12- lead electrocardiogram (ECG) 
measurements. In the healthy volunteer study, CVN424 in suspension was rapi[INVESTIGATOR_609740]; peak plasma concentration was usually attained between [ADDRESS_808412]-dose (median 1.5 h). When CVN424 was administered after a meal, the peak plasma 
concentration was delayed and decreased while total exposure was minimally increased compared 
to the same dose level administered under fasted conditions. With repeated once -daily dosing, 
trough plasma concentrations usually reached a steady- state level by [CONTACT_2006] 4, with a terminal 
elimination half -life of approximately 33 h. Accordingly, CVN424 pharmacokinetics  (PK) is 
appropriate for once-daily oral dosing, with or without food.  
In the Phase 2 study, exposure to CVN424 increased with dose level from 50 to 150 mg.  The 
increase in exposure with dose was slightly less than dose -proportional.  After CVN424 50 mg 
dosing, there was a trend for higher exposure in females compared with males.  There were no 
apparent differences between females and males after CVN424 150 mg dosing, and PK parameters 
were comparable.  After CVN424 50 mg dosing, maximum observed plasma concentration ( Cmax) 
and area under the plasma concentration -time curve  from time 0 to 6 h ( AUC 6) were slightly higher 
in the < median weight group compared with the ≥ median weight group.  Exposure parameters 
were generally comparable between weight groups after CVN424 150 mg dosing.   
In a Phase 2 study of CVN424 in patients diagnosed with Parkinson’s disease with motor 
fluctuations ([STUDY_ID_REMOVED]), 136 patients were in the primary efficacy analysis safety analysis 
set. After Screening , to establish baseline safety and efficacy assessments, patients were 
randomized in a 1:1:1 ratio into 1 of 3 study groups to receive once -daily low -dose (50 mg) 
CVN424, high- dose (150 mg) CVN424, or matching placebo on Day 0/Visit 1. Patients not 
randomized to placebo -initiated  treatment with 50mg CVN424 on Day 1 (Visit  2).  Thereafter, the 
low-dose group continued to receive 50mg per day, while the high- dose cohort increased their 
dosage to 150 mg CVN424 per day beginning on Day 8± 2 days (Visit 3) and continued this dose 
thereafter.  The study drug was self -administered each morning on an outpa tient basis as an oral 
suspension.  Efficacy and safety evaluations were made throughout the study on Visit 1 through 
Visit 7, inclusive according to the Schedule of Study Procedures  (Appendix A ).  Follow- up safety 
and efficacy assessments occurred on Day  35/Visit 7, approximately 7 days after the final study 
drug dose was taken on Day 27 ± 1. The primary efficacy endpoint for the study was OFF time.  
Treatment with CVN424 was associated with a statistically significant and clinically meaningful 
improvement (relative to placebo) in OFF time with the 150 mg dose.  This reduction in OFF time 
was accompanied by [CONTACT_609757]. Treatment with CVN424 150 mg reduced the average daily hours of OFF 
time relative to placebo at Day 27 in the Primary Efficacy Analysis Set.  Thus, this study met its 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 21 of 70
CVN424   
Study No. CVN424 -102 Page 17 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
primary efficacy endpoint with the CVN424 150 mg dose and combined CVN424 dose groups.  
On Day 27, the LS mean (± SE) for average daily hours of OFF time for the CVN424 150 mg vs 
placebo comparison was -1.30 (± 0.56) h; P = 0.0418 (Dunnett) and P = 0.0225 (MMRM).  
However, the CVN424 50 mg vs placebo comparison was not statistically significant at Day 27 (P 
= 0.3302 [Dunnett]; P = 0.1985 [MMRM]).  At Day 27, the LS mean (± SE) for the combined 
CVN424 vs placebo comparison was -1.02 (± 0.50) h; P = 0.0410 (MMRM).  Analysis of the 
Seco ndary Efficacy Analysis Set and a sensitivity analysis yielded results similar to the Primary 
Efficacy Analysis Set.  Treatment with CVN424 50 mg and CVN424 150 mg was associated with 
a non- statistically significant numerical increase in ON time without tr oublesome dyskinesia on 
Day 15 and Day 27 vs. placebo. ON time with troublesome dyskinesia was generally constant 
throughout the course of the trial; changes from baseline to Day 27 were less than 12 minutes.  In 
the CVN424 150 mg group, ON time with dyskinesia was generally constant throughout the study; 
the change from baseline was less than 6 minutes on Day 27.  Treatment with CVN424 50 mg and 
CVN424 150 mg was associated with an increase in ON time on Day 15 and Day 27; however, 
the differences between the CVN groups and placebo were not statistically significant.   
Treatment with CVN424 did not demonstrate significant benefit on Unified Parkinson’s Disease 
Rating Scale ( UPDRS ) Part I, Part III, Part IV Section A, and Part IV Section B scores.  Treatment  
with CVN424 150 mg was associated with a clinically meaningful numerical improvement on the 
UPDRS Part II scores (motor experiences of daily living) vs . placebo, but the difference compared 
to placebo did not reach statistical significance due to the small size of the study.  Treatment with 
CVN424 did not demonstrate significant benefit on the Clinical Global Impression Scale ( CGI) or 
the Patient Global Impression ( PGI) scores.  On Day 15 and Day 27, numerically higher 
percentages of CVN424 -treated patient s were considered CGI responders compared with the 
placebo group, but this difference did not reach statistical significance.  On Day 15 and Day 27, 
numerically higher percentages of CVN424- treated patients were considered PGI responders 
compared with the placebo group, but this difference did not reach statistical significance.  
Treatment with CVN424 150 mg led to numeric improvement in the Epworth Sleepi[INVESTIGATOR_609741], with numerical improvement compared to placebo on Day 15, Day 27, and Day 35  
(statistically significant difference on Day 15 only). 
At Day 15, there were statistically significant differences for the CVN424 150 mg vs placebo 
comparison (LS mean [± SE] = -1.35 [± 0.68]; P = 0.0493) and for the CVN424 50 mg vs CVN424 
150 mg comparison (LS mean = 1.72 [± 0.67]; P = 0.0119).  CVN424 50 mg vs . placebo favored 
the CVN424 50 mg group for reducing OFF time in the following subgroup population: age ≥ 
median.  CVN424 150 mg vs . placebo favored the CVN424 150 mg group for reducing OFF time 
in the following subgroup populations: age ≥ median; females; weight < median; no dopamine 
agonist; no monoamine oxidase or catechol -o-methyl transferase inhibitor; no amantadine; 
baseline UPDRS Part II Total Score < median and ≥ median; baseline UPDRS Part III Total Score 
≥ median; baseline ON time ≥ median; response rate defined as patients with ≥30% decrease in 
OFF time was significantly increased in the CVN424 150 mg group compared to placebo.  On Day 
27, 33.3%, 36.8%, and 56.8% of patients in the placebo, CVN424 50 mg, and CVN424 150 mg 
groups, respectively, achieved the definition of responder.  The P value for the CVN424 150 mg 
vs. placebo comparison was statistically significant (P = 0.0310).  Analysis of the Secondary 
Efficacy Analysis Set and a sensitivity analysis yielded results similar to the Primary Efficacy 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 22 of 70
CVN424   
Study No. CVN424 -102 Page 18 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
Analysis Set.  There were no significant differences for any treatment comparison in any analysis 
set for the percentage of patients meeting ascending OFF time reduction thresholds (≥0.5 hour, ≥1 
hour, ≥1.5 hours, ≥2 hours, ≥2.5 hours).  
The primary endpoint of the study was safety.  During the study (overall), there was a  higher 
incidence of  treatment -emergent adverse events  (TEAE) and treatment -related TEAEs among 
patients treated with CVN424 (both dose groups) compared to placebo. Overall, there was a higher 
incidence of TEAEs in the CVN424 150 mg than in the CVN424 50 mg group; however, 
treatment -related TEAEs had a similar incidence in the 50 mg and 150 mg CVN424 dose groups. 
There were no treatment -related serious adverse events ( SAE ) in this study, and there was [ADDRESS_808413] in 1 (2.1%) patient in the CVN424 [ADDRESS_808414] common TEAEs (preferred terms) were headache and nausea.  A total of 
6 patients developed headaches (1 [2.3%] patient, 1 [2.2%] patient, and 4[8.5%] patients in the 
placebo, CVN424 50 mg, and CVN424 150 mg groups, respectively).  A total of 6 patients 
developed nausea (1 [2.3%] patient, 2 [4.4%] patients, and 3 [6.4%] patients in the placebo, 
CVN424 50 mg, and CVN424 150 mg groups, respectively). Overall, treatment -related TEAEs 
were more common in the CVN424 groups than in the placebo group (9.1%, 17.8%, and 19.1% of 
patients in the placebo, CVN424 50 mg, and CVN424 150 mg groups, respectively) . Nausea was 
the most common treatment- related TEAE,  with a total of 4  (2.9%) patients experiencing 5 
treatment -related events (0 [0%] patients, 2  [4.4%] patients, and 2 [4.3%] patients in the placebo, 
CVN424 50mg, and CVN424 150 mg groups, respectively).  Hallucinations, somnolence, 
confusion, orthostatic hypotension, and dyskinesia were each observed in fewer than 2 CVN424 -
treated patients.  Overall, approximately 67% of treatment -related TEAEs were mild in severity; 
the remainder were moderate in severity. There were no severe treatment -related TEAEs.  There 
was a higher incidence of moderate treatment -related TEAEs in the CVN424 150mg group (8.5%) 
than in the CVN424 50 mg (2.2%) and placebo groups (4.5%). Overall, 6 (4.4%) patients 
discontinued study drug due to a TEAE: 2 (4.5%), 1 (2.2%), and 3 (6.4%) patients in the placebo, 
CVN424 50 mg, and CVN424 150 mg groups, respectively.   
Of these, 4 patients who received CVN424, 2 patients (1 each in the CVN424 50 mg and 150 mg 
groups) discontinued the study drug due to nausea. During the study, no medically significant 
treatment -related TEAEs (as defined in the protocol) occurred.  There were no notable changes in 
laboratory parameters, physical examinations, electrocardiograms ( ECGs ), and Beck Depression 
Inventory (BDI)  scores during the study.  However, patients receiving CVN424 did experience 
transient increases in blood pressure and pulse rate on Day [ADDRESS_808415] impulsivity as assessed by [CONTACT_156220] -Com pulsive Disorders 
(QUIP ) with the exception of sex on Day 15.  No statistically significant correlations were 
identified between 3-hour post- dose CVN424 concentration and ECG or vital signs parameters on  
Days [ADDRESS_808416] -hoc analyses on the PD diary data, conforming to the Food 
and Drug Administration ( FDA ) standardized analysis for the PD diary. The PD diary was 
normalized to a 16-hour waking day, required 44/[ADDRESS_808417] conducted for the full analysis set and confirmed the result of the primary analysis, with 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 23 of 70
CVN424   
Study No. CVN424 -102 Page 19 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
greater numeric improvement compared to placebo on the reduction in OFF time (CVN424 150 
had a 1.45 -hour benefit compared to placebo; nominal p=0.01) and improvement in ON time 
without troublesome dyskinesia (CVN424 had a 0.96 -hour benefit compared to placebo; 
p=0.098).ON time with troublesome dyskinesia was comparable to the primary analysis. A second 
post- hoc analysis was conducted using FDA standards for the PD diary analysis , excluding patients 
with a Baseline OFF time of [ADDRESS_808418] of 
CVN424 on reduction in OFF time (1.78- hour improvement vs. placebo for the 150 mg dose; 
nominal p=0.005) and improvement in ON time without troublesome dyskinesia (1.30-hour 
improvement vs. placebo for the 150 mg dose; nominal p=0.042) . ON time with troublesome 
dyskinesia was similar to the primary analysis.   
CVN424 is expected to be a pharmacological treatment f or PD participant s, as monotherapy or 
adjunctive to dopaminergic therapy, to elicit sustained improvement of motor activity with a 
reduced risk of troublesome dyskinesia compared with dopaminergic therapi[INVESTIGATOR_014]. As a novel, first -
in-class, non- dopaminergic drug for the symptomatic treatment of PD, CVN424 may become a 
significant addition to neurologists’ clinical armamentarium 
4.[ADDRESS_808419] OFF time that poorly impacts quali ty of life. Approved interventional 
procedures include deep brain stimulation (DBS)  and intrajejunal levodopa. Both are highly 
effective but require an invasive procedure and risk serious and significant short -term and long-
term AEs and device complications. Thus, additional non- invasive treatments are needed that can 
provide gr eater efficacy benefit s with low rates of dopaminergic AEs. 
The efficacy of CVN424 in animal models of PD and a prior phase 2a with PD patients supports 
its further investigation into the comparison of the in vivo  performance of solution to tablet 
formulation.  
A safety and pharmacokinetic (PK) study previously performed in 64 healthy volunteers supports 
the selected dose levels of CVN424 in this study. Section 6.2 outlines the justification for the planned dosages.  
 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 24 of 70
CVN424   
Study No. CVN424 -102 Page 20 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
5.0 STUDY OBJECTIVES AND ENDPOINTS  
5.1 Objectives  
Objectives  Endpoints  
Primary  Primary  
• To determine the relative bioavailability of 
150 mg of CVN424 administered in a single 
dose of suspension formulation compared to 
150 mg tablet . • The relative bioavailability of the CVN424 solution and 
CVN424 tablet formulation in the fasted state based on 
maximum observed plasma concentration (C max), time to 
reach C max (Tmax), and area under the plasma concentration -
time curve from time 0 to 96 hours (AUC 0-96h). 
 
• The ratio of the PK parameters between CVN424 solution 
and tablet in the fasted state will be calculated and 
summarized descriptively. In addition, a n analysis of 
variance (ANOVA) on log -transformed PK parameters 
(AUC 0-t, AUC 0-96h, C max) will be performed. Ratios of 
geometric means and 90% confidence intervals will be 
calculated. T max will be compared between CVN424 solution 
and CVN424 tablet . 
Secondary  Secondary  
• To establish the effects of food on the rate and 
extent of absorption of CVN424 150mg tablet when administered in fed conditions compared to administration under fasting conditions . 
 
• To assess the safety of the tablet under fast and 
fed conditions and suspension under fast 
conditions . • The ratio of the PK parameters between CVN424 tablets in 
the fed and fasted state will be calculated and summarized descriptively. In addition, an analysis of variance (ANOVA) on log- transformed PK param eters (AUC
0-t, AUC 0-96h, Cmax) 
will be performed. Ratios of geometric means and 90% 
confidence intervals will be calculated. T max will be 
compared between CVN424 tablets in the fed and fasted state. T
max and T lag will be compared between CVN424 
tablets in the fed and fasted state. 
 
• Assessment of safety as measured by [CONTACT_609758] (D/Cs) due to AE.  
Exploratory  Exploratory  
• Explore serum/plasma (e.g., potential 
characterization of drug metabolites) that may 
contribute to variability in CVN424 . 
 
• Assessment of urine concentrations and 
volumes to enable calculation of urine PK 
parameters where possible. • Potentially characterize metabolic enzyme and transporter 
polymorphisms . 
 
• Urine concentrations and volumes of CVN424 tablet 
formulation at pre -dose and 0- 12, [ADDRESS_808420]-dose. Urine PK parameters (cumulative amount of 
unchanged drug excreted into the urine [Ae], fraction of 
unchanged drug excreted in the urine [fe], and renal 
clearanc e [CL R]) to be determined where possible . 
 
  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808421] cross -over study under fasted and fed conditions, study 
in healthy participant s. 
Table 1  Study Schema  
      
Sequence  Dosing #1  
(Period 1 Day 1)   Dosing #2  
(Period 2 Day 1)   Dosing #3  
(Period 3 Day 1)  
1 (n=5)  Suspension (fasted)  
W a s h o u t  Tablet (fasted)  
W a s h o u t  Tablet (fed)  
   
2 (n=6)  Tablet (fasted)  Tablet (fed)  Suspension (fasted)  
   
3 (n=5)  Tablet (fed)  Suspension (fasted)  Tablet (fasted)  
   
4 (n=5)  Suspension (fasted)  Tablet (fed)  Tablet (fasted)  
    
5 (n=5)  Tablet (fasted)  Suspension (fasted)  Tablet (fed)  
   
6 (n=6)  Tablet (fed)  Tablet (fasted)  Suspension (fasted)  
     
 6.1.[ADDRESS_808422] cross -over 
sequences (designated as 1 through 6, respectively) in an ascending fashion. Sequences 1, 3, 4, 
and [ADDRESS_808423] 6 participants each.  
Each sequence will proceed through three cross -overs (suspension- fasted, tablet -fed, tablet -fasted) 
according to the schematic above, with dosing to occur on Day [ADDRESS_808424] of food on CVN424 bioavailability in tablet formulation, the single -dose 
administration will be administered after ingestion of a standardized high -fat, high- calorie meal 
according to FDA Guidance for Industry (Food -effect bioavailability and fed bioequivalence 
studies, Jun 2022).  Participants for all sequences will be admitted to the study unit [ADDRESS_808425] -dose. The total confinement for 
each period will be 5 nights per sequence (15 days total) unless extended at the discretion of the Investigator, e.g., for monitoring and/or management of AEs.  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808426] -dose PK has been collected, participants will be discharged from the clinical 
research unit (CRU) for the remainder of the w ashout period and return the day prior to their next 
dose. 
An outline of the study visit schedule is included in Appendix A . 
6.[ADDRESS_808427] crossover study under fasted and fed 
conditions in healthy participant s. The selected dose level (150 mg) is expected to provide a high 
level of GPR6 occupancy in brain tissue even at its steady- state nadir plasma concentration.  
Based on the Phase 2 data  (see Section 4.1) and a previous healthy volunteer study, the planned 
dose of CVN424 is  within the dose range previously shown to be safe and well- tolerated.  
AEs, physical exams, vital signs and weight, ECG findings, and clinical laboratory results are used 
as safety assessments to determine the relative bioavailability of the CVN424 suspension and tablet 
formulations. The plasma PK parameters will further elucidate the pharmacology  of CVN424  in 
the intended participant population. 
6.[ADDRESS_808428] (IRB) considers the risk is no longer 
acceptable for participant s participating in the study. 
6.3.2 Criteria for Premature Terminat ion or Suspension of Investigational Sites 
A study site may be terminated prematurely or suspended if the site (including the Investigator) is found in significant violation of Good Clinical Practice (GCP), protocol, or contractual agreement and is unable to ensure adequate study performance or otherwise permitted by [CONTACT_174360].  
If the Sponsor , IRB, or regulatory authority elects to terminate or suspend the trial or the 
participation of an investigational site, a trial -specific procedure for early termination or 
suspension will be provided by [CONTACT_1034] ; applicable investigational sites will follow the  
procedure during termination or trial suspension. 
6.3.3 Procedures for Premature Termination or Suspension of the Study or the 
Participation of Inve stigational Site(s) 
If the Sponsor, IRB,  or regulatory authority elects to terminate or suspend the study or the 
participation of an investigational site, a study -specific procedure for early termination or 
suspension will be provided by [CONTACT_1034] ; applicable investigational sites will follow the 
procedure during the course of termination or study suspension. 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 27 of 70
CVN424   
Study No. CVN424 -102 Page 23 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
7.0 PARTICIPANT  POPULATION  
Screening for eligible participants  will be performed within 28 days prior to randomization.  
7.1 Inclusion Criteria  
Participant  eligibility is determined according to the following criteria prior to entry into the study:  
1. In the Investigator's opi[INVESTIGATOR_1649], the participant  can understand and sign the Informed 
Consent Form (ICF)  and comply with all protocol requirements.  
2. The participant  is male or female adult who is [ADDRESS_808429] 45 kilograms (kg) (99 pounds [lbs]) and has a BMI between 
18.0 and 35.0 kg/m2, inclusive at Screening.  
4. The participant  is medically healthy with no clinically significant (CS) or relevant 
abnormalities in medical history, physical exam, vital signs, ECG, and laboratory evaluations (hematology, chemistry, and urinalysis) as assessed by [CONTACT_737]. 
5. Female participants  of childbearing potential and male participants  with female partners 
of childbearing potential must agree to either remain abstinent or use two methods of adequate and reliable contraception (see Section  9.1.12)  throughout the study and at least 
[ADDRESS_808430] dose of study drug has been taken. 
7.2 Exclusion Criteria  
Any participant  who meets any of the following criteria will not qualify for entry into the study: 
1. Vegetarian , Vegan, Lactose intolerant, or follows a Kosher diet. 
2. Evidence of clinically significant neurologic or other disorder or impairment that, in the opi[INVESTIGATOR_689], is reasonably expected to impact the ability of the participant to participate or confound the study results. 
3. A current or recent (within 6 months) gastrointestinal disease that would be expected to 
influence the absorption of drugs (i.e., a history of malabsorption, any surgical intervention known to impact absorption [e.g., bariatric surgery or bowel resection]). Note, history of cholecystectomy is permitted if there is no evidence of malabsorption per the Investigator. 
4. A history of cancer or other malignancy, with the exception of low- grade cervical 
intraepi[INVESTIGATOR_28601], low -grade (low -risk) prostate cancer, or [ADDRESS_808431] result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) 
antibody, or a human immunodeficiency virus (HIV) infection at Screening. 
6. Any clinically significant abnormalities in labs: biochemistry (including liver function test [LFT], estimated glomerular filtration rate [eGFR], and glucose), standard 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 28 of 70
CVN424   
Study No. CVN424 -102 Page 24 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
hematology with white blood cell (WBC) differential, c -reactive protein (CRP), 
coagulation tests, lipase, amylase, albumin, and calcium. 
7. A supi[INVESTIGATOR_174326] 80 to 160 mm Hg for systolic and 50 to 100 
mm Hg for diastolic, confirmed with up to two repeat tests at the Screening Visit; or symptomatic orthostatic hypotension, in the opi[INVESTIGATOR_689]. 
8. A resting heart rate outside the range of 40 to 100 beats per minute (bpm) confirmed with up to two repeat tests at the Screenin g Visit. Note that 40 -50 and 90-100 bpm may be 
permitted only at the discretion of the Investigator. 
9. Positive urine result for illegal drugs at Screening and Check-In, or history of illicit drug use or alcohol abuse within 1 year prior to the Screening Vis it. 
10. Received any investigational compound (defined as a drug that has not been FDA-approved) within [ADDRESS_808432] dose of study medication or within 5 half- lives 
of the investigational compound, whichever is greater. 
11. Within 14 or 28 days prior to randomization, ingested any of the following excluded medication, supplements, or food products: St. John’s wort, ginseng, kava, Ginkgo biloba, Chinese herbs, and melatonin, or known strong inhibitors/inducers of cytochrome P-4503A4/5, including rifampin, clarithromycin, ketoconazole, itraconazole. For full list of prohibited medications and dietary products, (See Table 2). 
12. Regularly uses nicotine-containing produc ts (including but not limited to cigarettes, 
electronic cigarettes, pi[INVESTIGATOR_27442], cigars, chewing tobacco, nicotine patch, or nicotine gum). The casual users (≤ 10 cigarettes/week) may participate; however, they must agree to refrain from 30 days before Day 0 (Inpatient Check-in) for the duration of the study or a positive urine cotinine test at Inpatient Check -in. 
13. Known history of coronary artery disease and hospi[INVESTIGATOR_609742], ischemic heart disease, or congestive heart failure within the 2 years prior to the 
screening visit.   
14. Any clinically significant medical, psychiatric, or laboratory abnormality that, in the judgment of the Investigator, is likely to interfere with study participation 
15. A history of major depression or risk of suicide according to the Investigator’s clinical judgment or has made a suicide attempt. 
16. Is a study site employee or an immediate family member of a study site employee.  
  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 29 of 70
CVN424   
Study No. CVN424 -102 Page 25 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
Table 2  Prohibited Medication and Dietary Products  
Use of the agents in  Table 2 (prescription or nonprescription) is prohibited from the time points 
specified until completion of all study activities.  
The following table defines the prohibited medications and dietary products:  
Prohibited Medication and Dietary Product  
Within 30 days before Randomization:  
• Nicotine -containing products  
Within 28 days before Randomization:  
• St. John’s wort, ginseng, kava, ginkgo biloba, Chinese herbs, and melatonin  
• Known strong inducers of cytochrome P-4503A4/5 or p -gp, including rifampin   
• Immunization vaccines: Inclusive of but not limited to H1N1 and flu vaccinations. 
Participants  who have received the COVID -[ADDRESS_808433] -study medication dosing.  
Within 14 days before Randomization:  
• Known strong inhibitors of cytochrome P -4503A4/5, including clarithromycin, ketoconazole, 
itraconazole  
• All prescription and non- prescription medications, herbal remedies, or vitamin supplements. 
Medication listed as part of acceptable birth  control ( Section  9.1.12) , hormone replacement 
therapy, and thyroid hormone replacement therapy medication will be allowed without dose 
changes during the study.  
Potential exceptions:  
• Occasional use of acetaminophen (~1 g/day) and 400mg ibuprofen TDS when required or 
other medication as approved by [CONTACT_1034]’s Medical Monitor on a case-by- case basis is 
allowed except on Day 1  
• Certain prescription medications may  be allowed on a case-by- case basis at the discretion of 
the Investigator and Sponsor 
 
  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 30 of 70
CVN424   
Study No. CVN424 -102 Page 26 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
7.3 Diet, Fluid, and Activity Control 
Participants  will refrain from the consumption of food and beverages containing the following: 
• Xanthines/caffeine: [ADDRESS_808434] PK sample in each period 
(small amounts of caffeine derived from normal foodstuffs, e.g., 250 mL/8 oz/ 1 cup decaffeinated coffee or other decaffeinated beverage per day, except for espresso; 45 g/1.5 oz chocolate bar, per day, would not be considered a deviation to this restriction). 
• Alcohol: [ADDRESS_808435] PK sample in each period. 
• Grapefruit/Seville orange: [ADDRESS_808436] -dose PK samples and monitor for 
safety and tolerability (Check -in through Day 5 for each of the three Periods). During confinement, 
with the exception of the dosing day (See  Section 7.3.1),  participant s will be provided [ADDRESS_808437] 
meals and a snack per day, each containing approximately 30% fat (re lative to the total calories). 
Each meal and/or snacks served at the CRU will be standardized , similar in caloric content and 
composition, and taken at approximately the same time in each period. When confined, standard 
meals and snacks will be provided at  appropriate times, except when they are required to fast. 
When confined in the CRU, participants will be required to fast from all food and drink except water between meals and snacks.  
The study menu should be recorded and submitted to the study file , with a copy provided to the 
Sponsor following treatment. Other fluids may be  given as part of meals and snacks but will be 
restricted at all other times throughout the confinement period.  
If a blood draw or any study procedure coincides with a meal, the blood draw will take precedence, 
followed by [CONTACT_609759]. 
Participant s will remain in bed at a semi- supi[INVESTIGATOR_19636] 4 hours following the dose 
administration, except as necessitated by [CONTACT_609760] (e.g., obtaining a 12-lead 
ECG). Participant s must refrain from strenuous exercise for 72 hours before Inpatient Check- in 
and until check-out. 
7.3.1 On Dosing Days: 
For the Suspension (fasted) and Tablet (fasted) portions:  Breakfast will not be provided on 
dosing days. Participants must fast for a minimum of [ADDRESS_808438] for an additional 4 hours after dosing and eat lunch following the 4-hour PK blood collection. Participants may consume water ad libitum except for 1 hour before and 1 hour after drug administration. 
 
For the Tablet (fed) portion (food effect):  CVN424 will be administered after ingesting a 
standardized high -fat, high- calorie meal according to FDA Guidance for Industry (Food -effect 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 31 of 70
CVN424   
Study No. CVN424 -102 Page 27 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
bioavailability and fed bioequivalence studies, June 2022). Participants will finish their breakfast 
in its entirety  within [ADDRESS_808439] 30 minutes (±5 
minutes) after beginning the meal. The meal start and stop times, and percentage of the meal consumed will be recorded in the source, and the appropriate electronic case report f orm (eCRF) 
for all meals served on dosing days. 
7.[ADDRESS_808440]. The Investigator may 
remove a participant  from the study if, in the Inves tigator’s opi[INVESTIGATOR_1649], it is not in the best interest of  
the participant  to continue the study. Participants  may be discontinued due to the following (not 
inclusive): 
1. The participant has experienced an AE that requires early termination because continued 
participation imposes an unacceptable risk to the participant’s health, or the participant is 
unwilling to continue because of the AE. 
2. Liver Function Test (LFT) Abnormalities  
Study medication should be discontinued immediately with appropriate clinical follow-up (including repeat laboratory tests until a participant’s laboratory profile has returned to normal/baseline status) if the following circumstances occur at any time during study medication treatment:  
– Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >8 × upper limit of normal (ULN), or  
– ALT or AST >5 × ULN and persists for more than 2 weeks, or 
– ALT or AST >3 × ULN in conjunction with elevated total bilirubin >2 × ULN or INR >1.5, or 
– ALT or AST >3 × ULN with appearance of fatigue,  nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash and/or eosinophilia (>5%). 
3. Significant protocol deviation. The discovery post- randomization that the participant 
failed to meet protocol entry criteria or did not adhere to protocol requirements and continued participation poses an unacceptable risk to the participant’s health. 
4. Lost to follow-up. The participant did not return to the clinic and attempts to contact [CONTACT_609761]. Attempts to reach the participant must be documented. 
5. Voluntary withdrawal. The participant (or participant’s legally acceptable representative) wishes to withdraw from the study. The reason for withdrawal, if provided, should be recorded in the eCRF.  
Note: Attempts should be made to determine  the underlying reason for the withdrawal 
and, where possible, the primary underlying reason should be recorded (e.g. , withdrawal 
due to an AE ; withdrawal due to relocation ). 
6. The Sponsor, IRB, or regulatory agency terminates the study. 
7. Other.  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 32 of 70
CVN424   
Study No. CVN424 -102 Page 28 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
The primary r eason for discontinuation or withdrawal of the participant from the study or study 
medication should be recorded in the eCRF using the following categories. For screen failure 
participant s, refer to  Section  9.1.14. 
Note: The specific reasons should be recorded in the “specify” field of the eCRF.  
7.[ADDRESS_808441] discontinue a participant’s study participation at any time during the study 
when the participan t meets the study discontinuation criteria described in Section 7.4. I n addition, 
a participant may discontinue their participation without giving a reason at any time during the study. Should a participant’s involvement be terminated, the primary criterion for termination must be recorded by [CONTACT_737]. In addition, efforts should be made to perform all procedures scheduled for the Early Termination Visit. Discontinued or withdrawn participants may be replaced at the Sponsor’s discretion. Participants who withdraw from the study prior to dosing may be replaced.  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 33 of 70
CVN424   
Study No. CVN424 -102 Page 29 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
8.0 CLINICAL TRIAL MATERIAL MANAGEMENT  
8.1 Study Medication and Materials  
This section contains information regarding all medication and materials provided directly by [CONTACT_9323]/or sourced by [CONTACT_609762], including important sections describing the management of clinical trial material.  
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling 
Study drug refers to CVN424 in both suspension and tablet formulations. 
In this protocol, the term study medication refers to all or any of the drugs defined below. 
[IP_ADDRESS] Investigational Drug 
CVN424  Suspension: 
The oral suspension drug product will be compounded by [CONTACT_174364], 
e.g., Infuserve America Inc. 
CVN424  oral suspension is prepared by [CONTACT_174365]424 drug substance in 2% Methocel, E15 
Premium LV Hydroxypropyl Methylcellulose (HPMC)/0.5% Tween 80 vehicle. CVN424 oral 
suspension is supplied to the clinical site in bottles with contents clearly labeled, along with the appropriate study information and caution statements. 
CVN424 Tablet: 
Patheon Milton Park [LOCATION_006] will manufacture the bulk drug product (150 mg tablets) and bottle it, 
and Patheon Allentown, US, will perform labeling and distribution of the study drug. 
The components of the CVN424 tablet include the CVN424 API, Colloidal Silicon Dioxide, 
Croscarmellose Sodium, Hydroxypropylcellulose, Magnesium Stearate, Mannitol, and Microcrystalline Cellulose.   
The tablets will be packaged in a high -density polyethylene (HDPE) bottle with an induction seal 
and a child -resistant cap; each bottle will contain 30 tablets.  
Ancillary Materials:  
Ancillary materials will be provided by [CONTACT_609763]/or the Sponsor based on 
availability. Unused ancillary materials provided by [CONTACT_609764]. 
8.1.[ADDRESS_808442] be maintained every working day; short excursions are allowed but must be evaluated by [CONTACT_1034]. 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 34 of 70
CVN424   
Study No. CVN424 -102 Page 30 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
8.1.3 Dose and Regimen  
Prior to dosing initiation, the Investigat or or Investigator’s designee will instruct the participant 
on dosing procedures. 
All dosing will occur while participant s are in the clinic under the supervision of the Investigator 
or designee and in fed or fasting conditions as outlined in Section 7.3. 
The exact time of dose will be recorded in the source documents and on the appropriate eCRF. 
The planned sequences to be studied are provided in Table 3.  
Table [ADDRESS_808443] Cross- Over Sequences  
      
Sequence  Dosing #1  
(Period 1 Day 1)  
(Study Day 0)   Dosing #2  
(Period 2 Day 1)  
(Study Day 14)   Dosing #3  
(Period 3 Day 1)  
(Study Day 28)  
1 (n=5)  Suspension (fasted)  
W a s h o u t  Tablet (fasted)  
W a s h o u t  Tablet (fed)  
   
2 (n=6)  Tablet (fasted)  Tablet (fed)  Suspension (fasted)  
   
3 (n=5)  Tablet (fed)  Suspension (fasted)  Tablet (fasted)  
   
4 (n=5)  Suspension (fasted)  Tablet (fed)  Tablet (fasted)  
    
5 (n=5)  Tablet (fasted)  Suspension (fasted)  Tablet (fed)  
   
6 (n=6)  Tablet (fed)  Tablet (fasted)  Suspension (fasted)  
     
 
8.1.4 Overdose  
An overdose is defined as a known, deliberate, or accidental administration of an investigational 
drug, to or by a study participant, at a dose above that assigned to that individual participant 
according to the study protocol. 
All cases of overdose (with or without associated AEs) will be  documented on an Overdose page 
of the eCRF, in order to capture this important safety information consistently in the database. 
Cases of overdose without manifested signs or symptoms are not considered AEs. AEs associated with an overdose will be documented on AE eCRF(s) according to Section 9.7.1. 
Serious adverse events (SAEs) associated with an overdose should be reported according to the 
procedure outlined in Section 9.7.2. 
In the event of an overdose, supportive measures should be employed as needed, e.g., administration of supportive therapy as dictated by [CONTACT_2299]’s clinical status, removal of 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808444] should be filed in the Investigator’s essential document file. The Investigator must maintain 100% accountability for all study medication received and dispensed during their entire participation in the study. Proper drug accountability includes, but is not limited to: 
• Continuously monitoring expi[INVESTIGATOR_1659] 
• Frequently verifying that actual inventory matches documented inventory 
• Verifying that the log is completed for the drug lot used to prepare each dose 
• Verifying that all containers used are documented accurately on the log 
• Verifying that required fields are completed accurately and legibly 
If any dispensing errors or discrepancies are discovered, the Sponsor must be notified immedia tely. 
The Investigator or designee must record the current inventory of all study medication on a 
Sponsor- approved drug accountability log. The following information will be recorded at a 
minimum: protocol number and title, name [CONTACT_12166], site identifier and number, 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 36 of 70
CVN424   
Study No. CVN424 -102 Page 32 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
description of study medication, expi[INVESTIGATOR_5695], and amount dispensed, including the initials of the 
person dispensing and receiving the study medication. The log should include all required information as a separate entry for each participant  to whom study medication is dispensed. 
Prior to site closure or at appropriate intervals, a representative from the Sponsor or its designee 
will perform clinical study material accountability and reconciliation before clinical study materials are returned to the Sponsor or its designee for destruction or destroyed at the site, as 
applicable. The Investigator will retain the original documentation regarding clinical study material accountability, return, and/or destruction, and copi[INVESTIGATOR_609743].  
The Investigator will be notified of any expi[INVESTIGATOR_609744]. On expi[INVESTIGATOR_609745], the site must complete all instructions ou tlined in the notification, including segregation of expi[INVESTIGATOR_609746]. 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808445] be obtained prior to the participant entering the study and before any 
protocol- related procedures are performed.  
9.1.2 Demographics, Medical History, and Medication History Procedure  
Demographic information to be obtained will include date of birt h, sex, ethnicity, race as described 
by [CONTACT_2299], smoking status, and caffeine consumption at Screening. 
Medical history to be obtained will include determining whether the participant has any significant 
conditions or diseases that stopped at or prior to signing the ICF. Ongoing conditions are 
considered concurrent medical conditions (see Section 9.6.2).  
Medication history information to be obtained includes any medication relevant to eligibility 
criteria stopped at or within 28 days before signing ICF. 
9.1.3 Physical Examination Procedure 
A physical examination performed by [CONTACT_609765]: (1) eyes; (2) ears, nose, throat; (3)  cardiovascular system; (4)  respi[INVESTIGATOR_2133]; (5) 
gastrointestinal system; (6)  dermatologic system; (7) extremities; (8) musculoskeletal system; (9) 
nervous system; (10) lymph nodes; and (11) other. 
Any a bnormal change from the baseline physical examination must be assessed as not clinically 
significant (NCS) or clinically significant (CS) by [CONTACT_609766]. Any CS change or new diagnosis as a result of a CS c hange, as determined 
by [CONTACT_737], will be recorded as an AE in source documentation and on the AE eCRF described in  Section  9.7.1. 
9.1.[ADDRESS_808446] weight and height measured while wearing indoor clothing and with 
shoes off. The BMI is calculated using metric units with the formula provided below: 
Height is recorded centimeters without decimal places and for w eight it is kilograms (kg) with [ADDRESS_808447]. BMI should be derived as:  
Metric:   BMI = weight (kg)/[height (m)]
[ADDRESS_808448] . 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 38 of 70
CVN424   
Study No. CVN424 -102 Page 34 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
Example:  
Height=176 centimeter ( cm) (or 1.76 m), weight=79.2 kg; BMI=79.2/1.762=25.57 kg/m2 
captured as 25.5 kg/m2.  
9.1.[ADDRESS_808449] 3 minutes. Vital signs include blood pressure (BP), pulse rate, respi[INVESTIGATOR_1487], and body 
temperature. Triplicate measurements will be taken at pre- dose, initial post -dose, and final study 
assessment to ensure accuracy unless values are unexpected and additional measurements are clinically indicated for confirmation. Additionally, abnormal or unexpected measurements are to be rechecked manually.  
Vital signs should be measured at the same time (+/ - 1 hour) of the day across visits if possible. 
When vital signs are scheduled at the same time as blood draws, the blood draw will take priority, 
and vital signs will be obtained within approximately [ADDRESS_808450] 
taken any medication other than the study medication (used from the  signing of ICF through the 
end of the study), and all medication, including vitamin supplements, over -the-counter 
medications, and oral herbal preparations, must be recorded in the eCRF. Documentation will include generic medication name, dose, unit, frequency, route of administration, start and end dates, and reason for use. Documentation of Concurrent Medical Conditions 
Concurrent medical conditions are those significant ongoing conditions or diseases that are present 
at the signing of ICF. This includes  CS laboratory, ECG, or physical examination abnormalities 
noted at Screening examination. The condition (i.e., diagnosis) should be described. 
9.1.7 Documentation of Concurrent Medical Conditions  
Concurrent medical conditions are those significant ongoing conditions or diseases that are present 
at the signing of ICF. This includes CS laboratory, ECG, or physical examination abnormalities noted at Screening examination. The condition (i.e., diagnosis) should be described. 
9.1.[ADDRESS_808451] 1 -minute apart at each scheduled time. The average of the 
ECG measurements will be used for determining eligibility. Additional unscheduled ECGs may 
be recorded where clinically necessary for participant safety.  
When an ECG is scheduled at the same time as blood draws or vital signs, then the blood draws and vital signs will take priority, and the ECG will be obtained within 30 minutes before or after the scheduled blood draw/vital sign assessment. If an ECG coincides with a meal, E CG will take 
precedence, followed by [CONTACT_45325].  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808452] period for ECG recordings. Should technical 
difficulties occ ur during the recording of the ECG, a reasonable attempt should be made to repeat 
the ECG shortly after the failed attempt.  
ECGs will be interpreted by [CONTACT_5944]. The Investigator or sub- Investigator will 
categorize the ECG findings using 1 of t he following categories: within normal limits, abnormal 
but not CS, or abnormal and CS. All 12- lead ECGs will be stored for manual measurement of 
intervals, if necessary. Twelve- lead ECGs will be recorded using an ECG machine that 
automatically calculates the heart rate and measures PR interval, RR interval, QRS interval, QT 
interval, and QTcF and QTcB (Fridericia’s and Bazett’s correction method) intervals . 
9.1.9 PK Sample Collection  
[IP_ADDRESS] Collection of Blood for PK Sampling 
Blood samples for analysis of CVN424 plasma  concentrations will be collected into chilled 
Vacutainers containing K 2EDTA.  
Instructions for sample processing and shipment are provided in a separate lab manual. 
In all sequences, serial blood samples to determine CVN424 concentrations in plasma will be 
collected according to the Schedule of Study Procedures ( Appendix A ). 
The PK samples will be collected at the nominal time point; all other assessments will be collected, before or after, within the allowable windows. The actual time of sample collection will be recorded on the source document and eCRF.  
Sampling time points may be adjusted or added based on the preliminary emerging PK data 
collected f rom prior sequence(s).  
[IP_ADDRESS] Collection of Urine for PK Sampling 
In Tablet (fasted) sequences only, urine samples for analysis of CVN424 (or its metabolites) 
concentration in urine will be collected: pre -dose (within 12 hours prior to dosing), 0- 12, 12-24, 
24-48, and 48-96- hours post -dose. Volume of urine collected is to be recorded. Instructions for 
sample processing and shipment are provided in a separate lab manual. 
[IP_ADDRESS] Bioanalytical Methods 
Plasma and urine concentrations of CVN424 will be measured by [CONTACT_5019]- performance liquid 
chromatography with tandem mass spectrometry using validated (for plasma) and qualified (for 
urine) assays.  
Plasma and urine samples will be archived for potential analysis of metabolites and/or target -
related biomarkers, if appropr iate. 
9.1.10 PK Parameters  
PK parameters of CVN424 will be derived using non- compartmental analysis methods from the 
concentration -time data for all evaluable participants. Actual sampling times, rather than scheduled 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 40 of 70
CVN424   
Study No. CVN424 -102 Page 36 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
sampling times, will be used in all computations involving sampling times. The following PK 
parameters will be determined from concentrations of CVN424 in plasma. 
 
Symbol/Term  Definition  
Plasma  
AUC t Area under the plasma concentration -time curve from the time of dosing to the time of the 
last measurable concentration  
AUC 0-96h Area under the plasma concentration -time curve from time 0 to 96 hours  
Cmax Maximum observed plasma concentration.  
Tmax Time to reach C max. 
 Additional PK parameters may be calculated as appropriate.  
9.1.11 Procedures for Clinical Laboratory Samples  
All samples will be collected in accordance with acceptable laboratory procedures .  
Table 4 lists the tests that will be obtained for each laboratory specimen.  
Table 4 Clinical Laboratory Tests 
Hematology  Serum Chemistry  Urinalysis  
RBC  
WBC with differential  
     (% and absolute)  
Hemoglobin  
Hematocrit  
Platelets  
PT/INR  ALT  
Albumin  
Alkaline phosphatase  
Amylase  
AST  
Total bilirubin  
Direct bilirubin  
Total protein  
Coagulation  
Creatinine  
CRP  
BUN/Urea  
Creatine kinase 
GGT  
eGFR  
Lipase  
Potassium  
Sodium  
Glucose  
Chloride  
Bicarbonate 
Calcium  pH 
Specific gravity  
Protein  
Glucose  
Blood  
Nitrite  
Microscopic Analysis  
(only if positive dipstick results):  
RBC/high power field  
WBC/high power field  
Epi[INVESTIGATOR_1663], casts etc.  
Diagnostic Screening:  
Serum  Urine/ Blood  
Serum hCG  
FSH Drug screen including amphetamines (AMP), 
barbiturates (BAR), benzodiazepi[INVESTIGATOR_1651] (BZO), 
cannabinoids, cocaine (COC), opi[INVESTIGATOR_858] (OPI), 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808453] be recorded as an AE in the participant’s source document s 
and on the appropriate eCRF. A CS laboratory abnormality that has been verified by [CONTACT_609767] a satisfactory explanation has been obtained. 
If participants experience ALT or AST >3 ×ULN, follow -up laboratory tests at a minimum, serum 
alkaline phosphatase, ALT, AST, total bilirubin, γ- glutamyl transferase (GGT), and international 
normalized ratio (INR) should be performed within a maximum of 7 days and preferably within 
48 to 72 hours after the abnormality was found. 
(Please refer to Section 7.[ADDRESS_808454] >3 ×ULN in conjunction with 
total bilirubin >2 ×ULN).  
If the ALT or AST remains elevated >3 ×ULN on these [ADDRESS_808455] the Medical Monitor for consideration of additional testing, close monitoring, possible discontinuation of study medication, and discussion of the re levant participant details, 
and possible alternative etiologies. The abnormality should be recorded as an AE (please refer to Section 9.7.3 for rep orting requirements). 
9.1.[ADDRESS_808456] dose of study medication, females of childbearing potential* must use two acceptabl e methods 
of contraception and must agree not to donate eggs; Nonsterilized** male participants who are sexually active with a female partner of childbearing potential* must use two acceptable method(s) 
of contraception throughout the duration of the study, and for [ADDRESS_808457] dose of study Hepatitis panel, including HBsAg and anti -HCV  
Human Immunodeficiency Virus (HIV) antibody  alcohol, methamphetamines, methadone 
(MET), methylenedioxymethamphetamine 
(MDMA), phencyclidine (PCP), tetrahydrocannabinol (TH C) 
Cotinine  
Urine Pregnancy Test  
Alcohol (may be performed via breath test or urine)  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808458] dose 
of study medication. 
*Females of childbearing potential are defined as any female who has experienced menarche and 
has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and is not postmenopausal.  
Menopause is defined as at least [ADDRESS_808459] regular menses with a follicle -stimulating 
hormone (FSH)>40 IU/L or at least [ADDRESS_808460] use condoms unless their partner’s postmenopausal status has been confirmed by [CONTACT_526143].  
**Sterilized males should be at least [ADDRESS_808461] use a barrier form of birth control ( for example, 
condom or diaphragm) to protect against the transfer of the study drug in any bodily fluids for [ADDRESS_808462] dose of study medication. 
Acceptable and highly effective methods of contraception are: 
• Abstinence is  defined as refraining  from heterosexual intercourse during the entire period 
of risk associated with the study treatments. The investigator will assess the reliability of 
abstinence concerning the duration of the clinical trial and the preferred and usual lifestyle of the participant.  
• Intrauterine device (IUD)  
• Surgical sterilization or postmenopausal 
• Condom, diaphragm, or cervical cap with spermicide  
• Hormonal contraception, including oral, injectable, transdermal, or implantable methods  
• Intrauterine hormone- releasing system  
• Bilateral tubal occlusion  
• Vasectomized partner (if the partner is the sole sexual partner of the woman of childbearing potential [WOCBP] participant and the vasectomized partner has received medical assessment of the surgical success)  
Participants  will be provided with information on acceptable methods of contraception as part of 
the participant’s  informed consent process and will be asked to sign a n ICF  stating that they 
understand the requirements for avoidance of pregnancy, egg donation, and sperm donation during the study. 
9.1.13 Pregnancy  
Women who are pregnant or breastfeeding will not be included in this study.  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808463] dose, should also be 
recorded following authorization from the participant’s  partner.  
If the pregnancy occurs during administration of active study medication, e .g., after Period  [ADDRESS_808464] listed in  Section 1.0. 
If the female participant  and/or female partner of a male participant  agrees to the primary care 
physician being informed, the Investigator should notify the primary care physician that the 
participant /female partner of the participant  was participating in a clinical study at the time she 
became pregnant and provide details of treatment the participant  received (blinded or unblinded, 
as applicable).  
All reported pregnancies will be followed up to final outcome  using the pregnancy form  and you 
may be asked to report the outcome . An evaluation after the birth of the child will also be 
conducted. 
9.1.[ADDRESS_808465] account for all participants who sign ICF. If the participant is not eligible at this 
visit, the Investigator should complete the eCRF screen failure form. 
The primary reason for screen failure is recorded in the eCRF using the following categories: 
• AE 
• Did not meet inclusion criteria or did meet exclusion criteria  
• Significant protocol deviation 
• Lost to follow-up 
• Voluntary withdrawal 
• Study termination  
• Other  
Participant numbers assig ned to participants who fail Screening should not be reused.  
If a participant fails Screening, but is later successfully rescreened, the data for the participant will 
be entered as if these were two separate participants. Therefore, the data should be entered as follows: 
1. The screen failure data should be entered as a screen failure participant.  
2. Rescreened participants should be assigned a new participant number and treated as a stand -alone participant. 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808466] be administered while participants are under observation in the clinical 
research unit. Following administration of the study medication, appropriate mouth and/or hand checks  will be performed to ensure that the dose is swallowed and noted in the source document. 
The date and time of each dose will be recorded in the source documents and on the eCRFs. An inventory of the study medication supplies dispensed will be performed by  [CONTACT_609768]’s source document records or equivalent. The exact dose time of consecutive participants may be staggered to facilitate logistics at the site . 
9.[ADDRESS_808467] administration of study drug (Period 1 Day 1). Additionally, all participants will be admitted to the study clinic the day prior to subsequent dosing days, See Schedule of Study Procedures ( Appendix A ). 
9.3.3 Dosing  
Participants will be dosed according to the schema (See Table 1) on Day 1 of Periods 1, 2, and 3. 
9.3.4 Washout and Discharge 
Participants will be discharged after 5 consecutive days for a 14- day washout period (following 
96-hour post-dose blood draw). 
9.3.5 Final Visit (discharge day from clinic)  
Participants will be confined to the study clinic for the first 96 hours of each washout period to 
permit supervised dosing of study drug and repeat study assessments.   
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808468] be recorded in the eCRF and in the partici pant's medical 
records.  Efforts will be made to perform all early termination procedures for safety purposes prior to discharge.  The early termination visit should be performed [ADDRESS_808469] complete the End of Study eCRF page for all participants receiving study 
medication.  
9.3.7 Follow- up Visit  
The Follow- up Visit will occur by [CONTACT_756] 14 days (±2) after the final dose of study drug unless 
abnormal CS findings are observed upon discharge. In these cases, participants must be brought 
back to the clinic for re -evaluation per the Investigator’s discretion. 
9.[ADDRESS_808470] the participants’ personal information to ensure optimal 
confidentiality and defined standard processes for sample and data collection, storage, analysis, and destruction. 
The sample will be labeled with a unique sample identifier similar to labeling in the main study 
but using a code different from the code attached to the health information and other clinical test results collected in the study. The sample and data are linked to personal health information with code numbers; the samples are stripped of all personally identifying information, but a key linking the samples to clinical analysis data exists. This link means that the participant may be identified but only indirectly. The code numbers will be kept secure by [CONTACT_120089]. 
9.[ADDRESS_808471] venipuncture or intravenous cannula is the preferred method of blood collection. Any other 
method will need to be approved by [CONTACT_1034]. The maximum volume of blood on any single 
day is approximately 111 mL, with the maximum amount not to exceed 500mL for the duration of study participation. 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808472] medical occurrence in a clinical investigation participant 
administered a drug whether or not considered drug- related (CFR Title 21, Part 312.32(a)); it does 
not necessarily have to have a causal relationship with this treatment.  
An AE can therefore be any unfavorable and unintended sign (e.g., a CS abnormal laboratory 
finding), symptom, or disease temporally associated with the use of a drug whether or not it is 
considered related to the drug. 
A treatment -emergent adverse event (TEAE) is an AE than begins on or after administration of the 
first dose of trial medication or an increase in severity or frequency on or after administration of 
the first dose of trial medication.  
9.6.[ADDRESS_808473] finding generally may: 
• Indicate a new diagnosis or unexpected worsening of a pre- existing condition. (Intermittent 
events for pre-existing conditions underlying disease should not be considered AEs) 
• Necessitate therapeutic intervention  
• Require an invasive diagnostic procedure 
• Require discontinuation or a change in dose of study medication or a concomitant medication 
• Be considered unfavorable by [CONTACT_109307] 
• AEs caused by a study procedure (e.g., a bruise after blood draw) should be recorded as an 
AE 
Diagnoses vs signs and symptoms: 
• Each event should be recorded to represent a single diagnosis. Accompanying signs 
(including abnormal laboratory values or ECG findings) or symptoms should NOT be 
recorded as additional AEs. If a diagnosis is unknown, sign(s) or symptom(s) should be recorded appropriately as an AE(s).  
Laboratory values and ECG findings: 
• Changes in laboratory values or ECG parameters are only considered to be AEs if they are 
judged to be CS (i.e., if some action or intervention is required or if the Investigator judges the change to be beyond the range of normal physiologic fluctuation). A laboratory re- test 
and/or continued monitoring of an abnormal value are not considered an intervention. In addition, repeated or additional noninvasive testing for verification, evaluation, or monitoring of an abnormality is not considered an intervention 
• If abnormal laboratory values or ECG findings are the results of pathology for which there is 
an overall diagnosis (e.g., increased creatinine in renal failure), the diagnosis only should be reported appropriately as an AE  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 47 of 70
CVN424   
Study No. CVN424 -102 Page 43 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
Pre-existing conditions: 
• Pre-existing conditions (present at the time of signin g of the ICF) are considered concurrent 
medical conditions and should NOT be recorded as AEs. Baseline evaluations (e.g., 
laboratory tests, ECG, X-rays, etc.) should NOT be recorded unless related Study Procedures (Appendix A ). 
• If a participant has a pre-existing epi[INVESTIGATOR_174343] (e.g., asthma, epi[INVESTIGATOR_002]), any occurrence 
of an epi[INVESTIGATOR_609747], serious, or severe in nature; that is, Investigators should ensure that the AE term recorded captures the change in the condition from Baseline (e.g., “worsening of…”) 
• If a participant has a concurrent degenerative condition (e.g., cataracts, rheumatoid arthritis), 
worsening of the condition should only be captured as an AE if occurring to a greater extent than that which would be expected. Again, Investigators should ensure that the AE term recorded captures the change in the condition (e.g., “worsening of…”)  
Worsening of AEs: 
• If the participant experiences a worsening or complication of an AE after starting 
administration of the study medication, the worsening or complication should be recorded 
appropriately as an AE. 
• If the participant experiences a wor sening or complication of an AE after any change in study 
medication, the worsening or complication should be recorded as a new AE. 
Changes in severity of AEs /Serious PTEs: 
• If the participant experiences changes in the severity of an AE, the event should be captured 
once, with the maximum severity recorded. 
Preplanned surgeries or procedures: • Preplanned procedures (surgeries or therapi[INVESTIGATOR_014]) scheduled prior to the signing of the ICF are 
not considered AEs. However, if a preplanned procedure is performed early (e.g., as an emergency) due to a worsening of the pre-existing condition, the worsening of the condition should be captured appropriately as an AE. Complications resulting from any planned surgery should be reported as AEs. 
Elective surgeries or pr ocedures:  
• Elective procedures performed where there is no change in the participant’s medical condition should not be recorded as AEs but should be documented in the participant’s source documents. Complications resulting from an elective surgery should be reported as AEs. 
Overdose: 
• Cases of overdose with any medication without manifested side effects are NOT considered 
AEs, but instead will be documented on an Overdose page of the eCRF. Any manifested side 
effects will be considered AEs and will be recorded on the AE page of the eCRF . 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808474] medical occurrence that at any dose:  
1. Results in DEATH  
2. Is LIFE -THREATENING  
• The term “life threatening” refers to an event in which the participant was at risk of 
death at the time of the event; it does not refer to an event that hypothetically might 
have caused death if it were more severe  
3. Requires inpatient HOSPI[INVESTIGATOR_117495] 
4. Results in persistent or significant DISABILITY/INCAPACITY  
5. Leads to a CONGENITAL  ANOMALY/CONGENITAL DISABILITY  
6. Is an IMPORTANT MEDICAL EVENT that satisfies any of the following: 
• May require intervention to prevent items 1 through 5 above 
• May expose the participant to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospi[INVESTIGATOR_059] 
o Examples of such medical events include allergic bronchospasm requiring intensive 
treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_12191], or the development of drug dependency or drug 
abuse. 
AEs that fulfill 1 or more of the serious criteria above are also considered SAEs and should be 
reported and followed up in the same manner (see Section 9.7.1 and  Section 9.7.2).  
9.6.4 Severity of AEs  
The different categories of intensity (severity) are characterized as follows:  
 
Mild:   The event is transient and easily tolerated by [CONTACT_2299].  
Moderate:  The event causes the participant discomfort and interrupts the participant’s 
usual activities.  
Severe:  The event causes considerable interference with the participant’s usual   
  activities.  
9.6.5 Causality of AEs 
The relationship of each AE to study medication(s) will be assessed using the following 
categories:  
Related:  An AE that follows a reasonable temporal sequence from the 
administration of a drug (including the course after withdrawal of the drug), or for which possible involvement of the drug can be argued, although factors other than the drug, such as underlying diseases, 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 49 of 70
CVN424   
Study No. CVN424 -102 Page 45 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
complications, concomitant drugs, and concurrent treatments, may also be 
responsible. 
Not Related:  An AE that does not follow a reasonable temporal sequence from the  
administration of a drug and/or that can reasonably be explained by [CONTACT_1604], such as underlying diseases, complications, concomitant drugs, and concurrent treatments.  
9.6.6 Relationship to Study Procedures  
Relationship (causality) to study procedures should be determined for all AEs. 
The relationship should be assessed as Related if the Investigator considers that there is a 
reasonable possibility that an event is due to a study procedure. Otherwise, the relationship should 
be assessed as Not Related.  
9.6.[ADDRESS_808475] signs/symptoms were noted by [CONTACT_135054]/or physician. 
9.6.8 Stop Date  
The stop date of the AE is the date at which the participant recovered, the event resolved but with 
sequelae, or the p articipant died.  
9.6.9 Frequency   
Epi[INVESTIGATOR_11742] (e.g., vomiting) or those which repeatedly occur over a period of consecutive days 
are intermittent. All other events are continuous. 
9.6.10 Action Concerning Study Medication  
• Drug withdrawn – a study medication is stopped due to the particular AE 
• Dose not changed – the particular AE did not require stoppi[INVESTIGATOR_007] a study medication 
• Unknown – only to be used if it has not been possible to determine what action has been 
taken  
• Not Applicable – a study medication was stopped for a reason other than the particular AE e.g., the study has been terminated, the participant died, dosing with study medication was already stopped before the onset of the AE 
9.6.11 Outcome 
• Recovered/Resolved – Participant  returned to first assessment status with respect to the AE  
• Recovering/Resolving – the intensity is lowered by [CONTACT_1734]: the diagnosis or signs/symptoms has almost disappeared; the abnormal laboratory value improved but has not returned to the normal range or baseline; the participant died from a cause other than the particular AE with the condition remaining “recovering/resolving” 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 50 of 70
CVN424   
Study No. CVN424 -102 Page 46 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
• Not recovered/not resolved – there is no change in the diagnosis, signs, or symptoms; the 
intensity of the diagnosis, signs/ symptoms, or laboratory value on the last day of the observed study period had got worse than when it started; is an irreversible congenital anomaly; the participant died from another cause with the particular AE/ state remaining “Not recovered/not resolved.” 
• Resolved with sequelae – the participant recovered from an acute AE/ but was left with 
permanent/significant impairment (e.g., recovered from a cardiovascular accident but with some persisting paresis) 
• Fatal – the AEs which are considered as the cause of death  
• Unknown – the course of the AE cannot be followed up due to hospi[INVESTIGATOR_323969]’s participation in the study 
9.7 Procedures  
9.7.1 Collection and Reporting of AEs 
[IP_ADDRESS] AE Collection Period  
Collection of AEs will commence from the time the p articipant signs the informed consent to 
participate in the study and continue until [ADDRESS_808476] dose. 
[IP_ADDRESS] AE Reporting  
At each study visit, the Investigator or designee will assess whether any subjective AEs have 
occurred. A neutral question, such as “How have you been feeling since your last visit?” may be 
asked. Participants may report AEs occurring at any other time during the study. Participants experiencing an AE must be monitored until the symptoms subside and any clinically relevant changes i n laboratory values have returned to baseline, or there is a satisfactory explanation for 
the change. All AEs will be documented on the AE page of the eCRF, whether or not the Investigator concludes that the event is related to the drug treatment. The following information will be documented for each event: 
1. Event term  
2. Start and stop date and time 
3. Frequency  
4. Severity  
5. Investigator’s opi[INVESTIGATOR_609748](s) (related or not related)  
6. Investigator’s opi[INVESTIGATOR_117497](s), including the details of the suspected procedure 
7. Action concerning study medication  
8. Outcome of event  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 51 of 70
CVN424   
Study No. CVN424 -102 Page 47 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
9. Seriousness 
9.7.2 Collection and Reporting of SAEs 
When an SAE occurs through the AE collection period, it should be reported according to the 
following procedure: 
An SAE form must be completed in English and signed by [CONTACT_609769] 
[ADDRESS_808477] onset or notification of the event. The information should be completed as 
fully as possible but contain, at a minimum: 
• A short description of the event and the reason why the event is categorized as serious 
• Participant  identification number 
• Investigator’s name 
• Name [CONTACT_174398](s) 
• Causality assessment  
The SAE form should be transmitted within [ADDRESS_808478] elevated >3 ×ULN on [ADDRESS_808479] >3 ×ULN and total bilirubin >2 ×ULN for which an 
alternative etiology has not been identified, the event should be recorded as an SAE and reported 
as per  Section 9.7.2. T he Investigator must contact [CONTACT_609770], such as acute viral hepatitis A or B or other acute liver disease or medical history/concurrent medical conditions. Follow -up laboratory tests 
will be at the discretion of the Investigator.  
9.[ADDRESS_808480] report becomes available at a later date, the 
Investigator should complete a follow -up SAE form or provide other written documentation and 
fax it immediately within 24 hours of receipt. Co pi[INVESTIGATOR_1672] 
(e.g., ECGs, laboratory tests, discharge summary, postmortem results) should be sent to the addressee if requested.  
All SAEs should be followed up until re suspension or permanent outcome of the event. The 
timelines and procedure for follow- up reports are the same as those for the initial report.  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 52 of 70
CVN424   
Study No. CVN424 -102 Page 48 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
9.8.1 Safety Reporting to Investigators, IRBs, and Regulatory Authorities  
The Sponsor will be responsible for reporting all suspected unexpected serious adverse reactions 
(S[LOCATION_003]Rs) and any other applicable SAEs to regulatory authorities and IRBs, as applicable, in 
accordance with national regulations in the countries where the study is conducted. Relative to the first awareness of the event by/or further provision to the Sponsor or Sponsor’s designee, S[LOCATION_003]Rs will be submitted to the regulatory authorities as an expedited report within [ADDRESS_808481] a copy of all expedited reports to their IRB  in accordance wit h national regulations.  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 53 of 70
CVN424   
Study No. CVN424 -102 Page 49 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
10.0 DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_609749], medical history, and concurrent conditions will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA). Drugs will be coded using the World Health Organization 
(WHO) Drug Dictio nary. All terms will be coded using the dictionary version available at the start 
of the study. 
10.1 CRFs (Electronic)  
Completed eCRFs are required for each participant who signs an informed consent. 
The Sponsor or its designee will supply investigative sites with access to eCRFs. The Sponsor will 
make arrangements to train appropriate site staff in the use of the eCRF. These forms are used to transmit the information collected in the performance of this study to the Sponsor and regulatory authorities. eCRFs must be completed in English. Data are transcribed directly onto eCRFs. 
After completion of the entry process, computer logic checks will be run to identify items such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by [CONTACT_39601] (or designees) and will be answered by [CONTACT_779].  
Corrections to eCRFs are recorded in an audit trail that captures the old information, the new 
information, the identification of the person making the correction, the date the correction was made, and the reason for the change. Reasons for significant corrections should additionally be included.  
The Investigator must review the eCRFs for completeness and accuracy and must sign and date 
the appropriate eCRFs as indicated. Furthermore, the Inve stigator must retain full responsibility 
for the accuracy and authenticity of all data entered on the eCRFs. 
eCRFs will be reviewed for completeness and acceptability at the study site during periodic visits 
by [CONTACT_1750]. The Sponsor or its designee w ill be permitted to review the participant’s 
medical and hospi[INVESTIGATOR_609750]. The completed eCRFs are the sole property of the Sponsor and should not be made available in any form to third parties, except for authorized representatives of appropriate governmental health or regulatory authorities, without the written permission of the Sponsor. 
10.[ADDRESS_808482] Retention  
The investigator agrees to keep the records stipulated in Appendix B  and those documents that 
include (but are not limited to) the study- specific documents, the identification log of all 
participants, medical records, temporary media such as thermal sensitive paper, source worksheets, 
all original signed and dated ICFs, participant authorization forms regarding the use of personal health information (if separate from the ICFs), an electronic copy of eCRFs, including the audit trail, and detailed  records of drug disposition to enable evaluations or audits from regulatory 
authorities, the Sponsor or its designees. Any source documentation printed on degradable thermal sensitive paper should be photocopi[INVESTIGATOR_63159]’s 
chart to ensure long -term legibility. Furthermore, ICH E6 Section 4.9.5 requires the Investigator 
to retain essential documents specified in ICH E6 (Section 8) until at least [ADDRESS_808483] 2 years after the investigation is discontinued and 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 54 of 70
CVN424   
Study No. CVN424 -102 Page 50 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
regulatory authorities are notified. In addition, ICH  E6 Section 4.9.5 states that the study records 
should be retained until an amount of time specified by [CONTACT_63227] 
a time specified in the Clinical Study Site Agreement between the Investigator and the Sponsor. Refer to the Phase 1 Site Specifications document for the Sponsor’s requirements on record 
retention. The Investigator should contact [CONTACT_609771]. 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 55 of 70
CVN424   
Study No. CVN424 -102 Page 51 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
11.0 STATISTICAL METHODS  
11.1 Statistical and Analytical Plans 
A statistical analysis plan (SAP) will be prepared and finalized prior to unblinding of the 
participant’s treatment assignment. This document will provide further details regarding the 
definition of analysis variables and analysis methodology to address all study objectives. 
A targeted data review will be conducted prior to unblinding of the participant’s treatment 
assignment. This review will assess the accuracy and completeness of the study database, 
participant evaluability, and appropriateness of the planned statistical methods. 
11.1.[ADDRESS_808484] 1 measurable 
plasma concentration . 
If any participants are found to be non- compliant with the dosing schedule or with incomplete 
data, a decision will be made on a case-by- case basis as to their inclusion in the analysis but will 
be presented in the participant listings. 
11.1.2 Analysis of Demographics and Other Baseline Characteristics  
Descriptive statistics (N, mean, SD, median, minimum, and maximum) will be generated for 
continuous demographic variabl es and baseline characteristics variables (age, height, weight, and 
BMI) CVN424 dose level, CVN424 overall, and overall. The number and percentage of 
participants in each class of the categorical demographic variables and baseline characteristics variables  (gender, ethnicity, and race) will be tabulated for each CVN424 formulation, CVN424 
overall, and overall. Individual participant demographic and baseline characteristics data will be listed . 
Demographic variables of screen failure participants and reasons  for screen failures will be 
summarized overall for participants who are screened but not enrolled in the study. Individual demographic characteristics, date of informed consent, and reason for screen failure will be listed . 
11.1.3 PK Analysis 
The concentration of CVN424 in plasma will be summarized by [CONTACT_609772]. Individual concentration data versus time will be presented in a data listing. Individual and mean plasma concentration data w ill be presented 
graphically.  Descriptive statistics (arithmetic mean, SD, median, minimum and maximum) will be used to summarize the plasma PK parameters for CVN424. In addition, geometric mean and coefficient of variation will be computed. 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808485] of fed/fasting state on PK and bioavailability of CVN424 will be characterized. Plots of C
max and AUCs, as well as dose- normalized C max and AUCs, will be generated. 
A more detailed analysis will be presented in the SAP.  
11.1.4 Safety Analysis 
[IP_ADDRESS] AEs 
All AEs will be coded by [CONTACT_9313] (SOC) and preferred term (PT) using MedDRA. 
Treatment -emergent AEs with onset occurring within 30 days (onset date – last date of dose +1 
≤30) after  study drug administration will be listed and included in the summary tables. Treatment -
emergent AEs will be summarized by [CONTACT_609773]424 formulation, if in the fed or fasted state, and CVN424 overall by [CONTACT_3592]. The following summary tables will be included in the report: summary of TEAEs and drug- related AEs, relationship of AEs to study drug (related vs. not 
related), severity of AEs, and related AEs. AEs leading to study drug discontinuation and SAEs will be listed. Data listings will be provided for all AEs, TEAEs, AEs leading to study drug discontinuation, and SAEs. All AEs will be listed . 
[IP_ADDRESS] Clinical Laboratory Evaluation 
Individual results of laboratory tests from hematology, chemistry, and urinalysis that are abnormal 
and CS will be summarized and listed. Baseline, post -dose, and change from baseline to post -dose 
laboratory data will be summarized for each CVN424 dose level and CVN424 overall. All clinical laboratory data will be listed . 
[IP_ADDRESS] Vital Signs 
Individual results of vital signs that are abnormal and CS will be summarized and listed. Baseline, 
post- dose, and changes from Baseline in vital sign measurements will be summarized by [CONTACT_609774]424 dose level and CVN424 overall. All vital sign data will be provided in the data listings. 
[IP_ADDRESS] ECGs  
Individual result s of quantitative ECG parameters from the [ADDRESS_808486] -dose, and changes from baseline in 
quantitative ECG parameters will be summarized by [CONTACT_609773]424 dose level and CVN424 
overall. Shift tables may be generated for the Investigator’s ECG interpretations that changed from 
baseline to the post -dose collections by [CONTACT_609775]. All ECG data will be provided in the 
data listings . 
[IP_ADDRESS] Other Variables 
Physical exam findings and sui cidal assessments will be presented in data listings.  
11.[ADDRESS_808487] periods. 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 57 of 70
CVN424   
Study No. CVN424 -102 Page 53 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
11.3 Determination of Sample Size 
It is planned to enroll up to 32 male or female participants for participation in this study. 
Based on previous PK studies with CVN424, it was determined 28 participants would be needed 
to show bioequivalence, assuming an intra -participant CV of 16% and an expected ratio of 1.10. 
[ADDRESS_808488] 28 evaluable participants.  
 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 58 of 70
CVN424   
Study No. CVN424 -102 Page 54 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
12.0 QUALITY CONTROL AND QUALITY ASSURANCE  
12.1 Study -Site Monitoring Visits  
Monitoring visits to the study site will be made periodically during the study to ensure that all 
aspects of the protocol are followed. Source documents will be reviewed for verification of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. The Investigator and institution guarantee access to source documents by [CONTACT_4885] (contract research organization) and by [CONTACT_1201]. 
All aspects of the study and its documentation will be subject to review by [CONTACT_16015] 
(as long as blinding is not jeopardized), including but not limited to the Investigator’s Binder, 
study medication, participant medical records, informed consent documentation, documentation 
of participant authorization to use personal health information (if separate from the ICFs), and review of eCRFs and associated source documents. It is important that the Investigator and other study personnel are available during the monitoring visits and that sufficient time is devoted to the process.  
12.[ADDRESS_808489] to study participants. Should other unexpected circumstances arise that require deviation from protocol-specified procedures, the Investigator should consult with the Sponsor or designee (and IRB, as required) to determine the appropriate course of action. There will be no exemptions (a prospectively approved deviation) from the inclusion or exclusion criteria. 
The site should document all protocol deviations in the participant’s source documents. In the 
event of a significant deviation, the site should notify the Sponsor or its designee (and IRB or EC, 
as required). Significant deviations include, but are not limited to, those that involve fraud or misconduct, increase the health risk to the participant, or confound interpretation of primary study assessment. A Protocol Deviation Form should be completed by [CONTACT_609776]. 
Every attempt will be made to collect each PK blood sample at the designated time point, an d the 
actual time of each blood sample will be recorded on the source document and eCRF. Table 1 
defines the windows allowed for sample collections .  
Protocol Deviation Forms are to be completed for PK samples collected outside of the following 
intervals: 
Table 5  Windows for PK Blood Sample Collection 
Minutes  Nominal Sampling Time  
±[ADDRESS_808490] -dose to ≤6 hours  
±10 >[ADDRESS_808491] -dose 
±15 >12 hours to 24 hours  
±30 >24 hours  
 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808492] the site in advance to arrange an 
auditing visit. The auditor may ask to visit the facilities where laboratory samples are collected, 
where the medication is stored and prepared, and any other facility used during the study. In addition, there is the possibility that this study may be inspected by [CONTACT_17513]. If the study site is contact[CONTACT_63224] a regulatory body, the Sponsor should be notified immediately. The Investigator and institution guarantee access for quality assurance auditors to all study documents as described in Section 12.1.  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.[ADDRESS_808493] for the individual participants (i .e., 
participants ) according to the protocol, the ethical principles tha t have their origin in the 
Declaration of Helsinki, and the ICH Harmonised Tripartite Guideline for GCP. Each investigator 
will conduct the study according to applicable local or regional regulatory requirements and align his or her conduct in accordance w ith the “Responsibilities of the Investigator” that are listed in 
Appendix B . The principles of Helsinki are addressed through the protocol and through appendices 
containing requirements for informed consent and investigator responsibilities. 
13.[ADDRESS_808494] be constituted according to the applicable state and federal/local requirements of each 
participating region. The Sponsor or designee will require documentation noting all names and 
titles of members who make up the respective IRB. If any member of the IRB has direct participation in this study, written notification regarding his or her abstinence from voting must 
also be obtained. Those Americas sites unwilling to provide names and titles of all members due to privacy and conflict of interest concerns should instead provide a Federal Wide Assurance 
Number or comparable number assigned by [CONTACT_9092]. 
The Sponsor or designee will supply relevant documents for submission to the respective IRB for 
the protocol’s review and approval. This protocol, the Investigator’s Brochure, a copy of the ICFs, 
and, if applicable, participant recruitment materials and/or advertisements and other documents required by [CONTACT_609777] a central or local IRB for approval. The IRB’s  written approval of the protocol and participant informed consent must be 
obtained and submitted to the Sponsor or designee before the commencement of the study (i.e., before shipment of the Sponsor -supplied drug or study- specific screening activity). The IRB 
approval must refer to the study by [CONTACT_1764], number, and version date; identify versions of other documents (e.g.,  ICF) reviewed; and state the approval date. The Sponsor will ship the 
drug/notify the site once the Sponsor has confirmed the adequacy of site regulatory documentation and, when applicable, the Sponsor has received permission from a competent authority to begin the trial. Until the site receives drug/notification, no protocol activities, including screening, may occur . 
Sites must adhere to all requirements stipulated by [CONTACT_63217]. This may include 
notification to the IRB regarding protocol amendments, updates to the ICF, recruitment materials intended for viewing by [CONTACT_4317], local safety reporting requirements, reports, and updates regarding the ongoing review of the study at intervals specified by [CONTACT_35974], and submission of the Investigator’s final status report to IRB. All IRB approvals and relevant documentation for these items must be provided to the Sponsor or designee. 
Participant  incentives should not exert undue influence for participation. Payments to participants  
must be approved by [CONTACT_282754]. 
13.2 Participant  Information, Informed Consent, and Participant  Authorization 
Written consent documents will embody the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all applicable laws and regulations. The ICF, participant  authorization form (if applicable), and  
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 61 of 70
CVN424   
Study No. CVN424 -102 Page 57 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
participant  information sheet (if applicable) describe the planned and permitted uses, transfers, and 
disclosures of the participant ’s personal and personal health information for purposes of 
conducting the study. The ICF and the participant  information s heet (if applicable) further explain 
the nature of the study, its objectives, and potential risks and benefits, as well as the date informed 
consent is given. The ICF  will detail the requirements of the participant and the fact that he or she 
is free to wi thdraw at any time without giving a reason and without prejudice to his or her further 
medical care.  
The investigator is responsible for the preparation, content, and IRB approval of the ICF and if 
applicable, the participant  authorization form. The ICF, participant  authorization form (if 
applicable), and participant  information sheet (if applicable) must be approved by [CONTACT_609778]. 
The ICF, participant  authorization form (if applicable), and participant  information sheet (if 
applicable) must be written in a language fully comprehensible to the prospective participant . It is 
the responsibility of the investigator to explain the detailed elements of the ICF, participant  
authorization form (if applicable), and participant  informat ion sheet (if applicable) to the 
participant . Information should be given in both oral and written form whenever possible and in 
the manner deemed appropriate by [CONTACT_1201]. In the event the participant  is not capable of rendering 
adequate written informed co nsent, then the participant ’s legally acceptable representative may 
provide such consent for the participant  in accordance with applicable laws and regulations. 
The participant , or the participant ’s legally acceptable representative, must be given ample 
opportunity to: (1) inquire about details of the study and (2) decide whether or not to participate in 
the study. If the participant , or the participant ’s legally acceptable representative, determines he or 
she will participate in the study, then the ICF and participant  authorization form (if applicable) 
must be signed and dated by [CONTACT_2299] , or the participant’s legally acceptable representative, 
at the time of consent and prior to the participant  entering into the study. The participant  or the 
partici pant’s legally acceptable representative should be instructed to sign using their legal names, 
not nicknames, using blue or black ballpoint ink. The investigator must also sign and date the ICF  
and participant  authorization (if applicable) at the time of c onsent and prior to participant  entering 
into the study; however, the sponsor may allow a designee of the investigator to sign to the extent permitted by [CONTACT_1289].  
Once signed, the original ICF, participant  authorization form (if applicable), and participant  
information sheet (if applicable) will be stored in the investigator’s site file. The investigator must document the date the participant  signs the informed consent in the participant ’s medical record. 
Copi[INVESTIGATOR_113903], the signed participant  authorization form (if applicable), and participant 
information sheet (if applicable) shall be given to the participant . 
All revised ICFs must be reviewed and signed by [CONTACT_607338]’s legally acceptable represent ative in the same manner as the original informed consent. The date 
the revised consent was obtained should be recorded in the participant’s objectives, and potential risks and benefits, as well as the date informed consent is given. The ICF will detail the requirements of the participant and the fact that they are free to withdraw at any time without providing a reason and without prejudice to their other medical care. 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 62 of 70
CVN424   
Study No. CVN424 -102 Page 58 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
The Investigator is responsible for the preparation, content, IRB approval of the ICF and, if 
applicable, the participant authorization form. The ICF, participant authorization form (if applicable), and participant information sheet (if applicable) must be approved by [CONTACT_609779], participant authorization for m (if applicable), and participant information sheet (if 
applicable) must be written in a language fully comprehensible to the prospective participant. It is 
the responsibility of the Investigator to explain the detailed elements of the ICF, participant authorization form (if applicable), and participant information sheet (if applicable) to the 
participant. Information should be given in both oral and written form whenever possible and in the manner deemed appropriate by [CONTACT_1201]. In the event the participant is not capable of rendering adequate written informed consent, the participant’s legally acceptable representative may provide such consent for the participant in accordance with applicable laws and regulations. 
The participant, or the participant’s lega lly acceptable representative, must be given medical 
record, and the participant should receive a copy of the revised ICF. 
13.3 Participant  Confidentiality  
The Sponsor and designees affirm and uphold the principle of the participant’s right to protection 
agains t invasion of privacy. Throughout this study, a participant’s source data will only be linked 
to the Sponsor’s clinical study database or documentation via a unique identification number. As permitted by [CONTACT_1763], limited participant attributes, such as sex, age, or date of birth, and participant initials may be used to verify the participant and the accuracy of the participant’s unique identification number. 
To comply with ICH Guidelines for GCP and to verify compliance with this  protocol, the Sponsor 
requires the Investigator to permit its monitor or designee’s monitor, representatives from any 
regulatory authority (e.g., FDA, Medicines and Healthcare products Regulatory Agency, Pharmaceuticals, and Medical Devices Agency), the S ponsor’s designated auditors, and the 
appropriate IRBs  to review the participant’s original medical records (source data or documents), 
including, but not limited to, laboratory test result reports, ECG reports, admission and discharge summaries for hospi[INVESTIGATOR_1684] a participant’s study participation, and autopsy reports. Access to a participant’s original medical records requires the specific authorization of the participant as part of the informed consent process (see Section 9.1.1).  
Copi[INVESTIGATOR_609751] (i.e., participant name, address, and other identifier fields not collected on the participant’s eCRF).  
13.[ADDRESS_808495] results and all data derived 
by [CONTACT_609780]. During and after the study, only the Sponsor may make study information available to other study Investigators or regulatory agencies, except as required by [CONTACT_6617]. Except as otherwise allowable in the clinical study site agreement, any public 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 63 of 70
CVN424   
Study No. CVN424 -102 Page 59 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
disclosure (including publicly accessible websites) related to the protocol or study results, other 
than study recruitment materials and/or advertisements, is the sole responsibility of the Sponsor. 
The Sponsor may publish any data and information from the study, including data and information 
generated by [CONTACT_737], without the consent of the Investigator. Manuscript authorship for 
any peer -reviewed publication will appropriately reflect contributions to the production and review 
of the document. All publications and presentations must be prepared in accordance with this section and the Clinical Study Site Agreement. In the event of any discrepancy between the protocol and the Clinical S tudy Site Agreement, the Clinical Study Site Agreement will prevail. 
The Sponsor may publish any data and information from the study (including data and information 
generated by [CONTACT_737]) without the consent of the Investigator. 
13.4.2 Clinical Trial Registration  
In order to ensure that information on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulations, and guidance, the Sponsor will register this clinical trial 
on ClinicalTrials.gov (and possibly on other publicly acc essible websites) before the start of the 
study.   
Sponsor contact [CONTACT_3031], along with the Investigator’s city, state, country, and recruiting 
status, will be registered and available for public viewing. Once participants receive the 
Investigator's contact [CONTACT_3031], they may call the site and request enrollment into the trial. The investigative site(s) are encouraged to handle such trial inquiries according to their established participant screening process. If the caller asks additional questions beyond the topic of trial enrollment, they should be referred to the Sponsor. 
13.4.[ADDRESS_808496] the results on ClinicalTrials.gov 
or other publicly accessible websites, as req uired by [CONTACT_174391]/or 
regulations. 13.[ADDRESS_808497] be insured in accordance with the regulations applicable to the 
site where the participant is participating. If a local underwriter is required, then the Sponsor or 
Sponsor’s designee will obtain clinical study insurance against the risk of injury to clinical study participants. Refer to the Clinical Study Site Agreement regarding the Sponsor’s policy on participant compen sation and treatment for an injury. If the Investigator has questions regarding 
this policy, they should contact [CONTACT_16015]. 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 64 of 70
CVN424   
Study No. CVN424 -102 Page 60 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
14.0 REFERENCES  
 
American Parkinson Disease Association. https://www.apdaparkinson.org/what -is-parkinsons/, 
accessed on 26 Jan 2018. 
Assessing the Effects of Food on Drugs in Investigational New Drugs and New Drug Applications -
Clinical Pharmacology Considerations; Guidance for Industry; Availability (Jun 2022). 
Dunnett, C.W. (1964)  New tables for multiple comparisons with a control, Biometrics Vol. 20, 
No. 3. 482-491. 
FDA Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials 
for Therapeutics in Adult Healthy Volunteers. US Dept of Health and Human Services, Food 
and Drug Administration, Center for Drug Evaluation and Research. [ADDRESS_808498]. Br J Clin Pharmacol. 2020 
Jul;86(7):1377-1386. doi: 10.1111/bcp.[ZIP_CODE]. 
Kaufmann P, Ort M, Golor G, Kornberger R, Dingemanse J. Multiple -dose clinical pharmacology 
of the selective orexin -[ADDRESS_808499] -539313. Prog Neuropsychopharmacol Biol 
Psychiatry. 2021 Jun 8;108:110166. doi: 10.1016/j.pnpbp.2020.110166.  
Salvadore G, Bonaventure P, Shekhar A, Johnson PL, Lord B, Shireman BT, Lebold TP, 
Nepomuceno D, Dugovic C, Brooks S, Zuiker R, Bleys C, Tatikola K, Remmerie B, Jacobs GE, Schruers K, Moyer J, Nash A, Van Nueten LGM, Drevets WC. Translational evaluation 
of novel selective orexin -[ADDRESS_808500] JNJ -61393215 in an experimental model for 
panic in rodents and humans. Transl Psychiatry. 2020 Sep 7;10(1):308. doi: 10.1038/s41398-020-[ZIP_CODE]-9. 
Wichmann T, DeLong MR, Guridi J, Obeso JA. Milestones in research on the pathophysiology of 
Parkinson's disease. Mov Disord. 2011 May;26(6):1032- 41. doi: 10.1002/mds.[ZIP_CODE]. 
PMID: 21626548; PMCID: PMC4272856. 
 
    
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 65 of 70
CVN424   
Study No. CVN424 -102 Page 61 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
Appendix A: Schedule of Study Procedures  
 
1 Assessments to be completed on final in- patient day and will be repeated if AE requires in -person follow -up 
2 Once eligibility has been confirmed by [CONTACT_609781]  
3 Assessments to include HR, BP, and temperature  
4 Height only at screening  
5 Part of safety assessments (Pre and 24h post -dose)  Overall Study Day #  -28 to -2 -1 0 1-4 5-12 13 14 15-18 19-26 27 28 29-32 33 +/ - 2 
Period    1 2 3  
Day  0 1 2-5 6-13 14 1 2-5 6-13 14 1 2-5 15 +/ - 2 
    Washout   Washout     
   Inpatient   Inpatient   Inpatient   
 Screening  Check -
in Dosing    Check -in Dosing  
Day   Check -in Dosing   Follow -
Up/ET1 
Informed Consent  X             
Inclusion/Exclusion 
Criteria  X             
Review ICF and I/E  X X    X    X    
Demographics and 
Medical History  X             
Randomization2  X            
Concomitant 
medications  X X X X  X X X  X X X X 
Participant Admission 
to CRU   X    X    X    
Vital signs3 X X X X  X X X  X X X X 
Weight, height, and 
BMI4  X            X 
Urinalysis5 X  X X   X X   X X X 
Urine Drug Screen  X X    X    X    
Cotinine Screen   X    X    X    
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 66 of 70
CVN424   
Study No. CVN424 -102 Page 62 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
 
6 Full PE at Screening, Medical Assessment pre-dose (within 24 hours prior to dosing) and [ADDRESS_808501]-menopausal women (defined as continuous amenorrhea of at least 2 years and not surgically sterile)  
[ADDRESS_808502] 12 -lead ECG will be recorded at Screening and on Days 0, 10, and 20 pre -dose [within 1 h prior to dosing] and 3h (+/ -15 minutes) post -dose. Triplicate 
standard 12-lead ECG will also be re corded at Early Termination (if applicable)  
12 Plasma Sampling: Predose (within 15 minutes prior to dosing; 60 minutes for the fed treatments), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84 and 96h  
13 For tablet fasted sequence: Predose (for bio analysis), 0 -12, 12-24, 24- 48, 48-96h.  Volume of urine collected needs to be recorded  
14 Sequences  1, 2, 4, 5  
15 Sequences  1, 3, 5, 6 
16 Sequences  2, 3, 4, 6 
17 Sequences  1, 4 will be dosed with suspension; 2,3,5,[ADDRESS_808503]  X             
Clinical laboratory 
tests7 X X X X   X X   X X X 
Pregnancy Test8 X X  X  X  X  X   X 
FSH9 X             
C-SSRS10 X X  X  X X X  X X X X 
ECG11 X  X    X    X  X 
PK Blood Collection12    X X   X X   X X  
PK Urine13   X X   X X   X X  
Overnight Fasting   X14    X15    X16    
CVN424 Dosing17   X    X    X   
AE Assessment   X X X  X X X  X X X X 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 67 of 70
CVN424   
Study No. CVN424 -102 Page 63 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
Appendix  B: Responsibilities of the Investigator 
Clinical research studies Sponsored by [CONTACT_609782].  
The Investigator agrees to assume the following responsibilities. 
1. Conduct the study in accordance with the protocol. 
2. Personall y conduct or supervise the staff who will assist in the protocol. 
3. Ensure that study related procedures, including study specific (non routine/nonstandard 
panel) screening assessments are NOT performed on potential participants , prior to the 
receipt of writ ten approval from relevant governing bodies/authorities. 
4. Ensure that all colleagues and employees assisting in the conduct of the study are informed of these obligations. 
5. Secure prior approval of the study and any changes by [CONTACT_609783] s 
to local regulatory requirements. 
6. Ensure that the IRB will be responsible for initial review, continuing review, and 
approval of the protocol. Promptly report to the IRB  all changes in research activity and 
all anticipated risks to participants . Make at least yearly reports on the progress of the 
study to the IRB  and issue a final report within 3 months of study completion. 
7. Ensure that requirements for informed consent, as outlined in local regulations, are met. 
8. Obtain valid ICF from each participant  who participates in the study and document the 
date of consent in the participant ’s medical chart. Valid informed consent is the most 
current version approved by [CONTACT_1201] . Each ICF should contain a participant  authorization 
section that describes the uses and d isclosures of a participant ’s personal information 
(including personal health information) that will take place in connection with the study. If an ICF does not include such a participant authorization, then the Investigator must obtain a separate particip ant authorization form from each participant or the participant ’s 
legally acceptable representative.  
9. Prepare and maintain adequate case histories of all persons entered into the study, including eCRFs, hospi[INVESTIGATOR_1097], laboratory results, etc. , and mainta in these data for a 
minimum of [ADDRESS_808504] and receive written approva l from the 
Sponsor before disposing of any such documents. 
10. Allow possible inspection and copying by [CONTACT_174394]- specified 
essential documents.  
11. Maintain current records of the receipt, administration, and disposition of Sponsor-supplied drugs, and return all unused Sponsor-supplied drugs to the Sponsor.  
12. Report adverse reactions to the Sponsor promptly. In the event of an SAE, notify the Sponsor within 24 hours. 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 68 of 70
CVN424   
Study No. CVN424 -102 Page 64 of 64 
Clinical Protocol Version 1.0  30 Aug 2022 
 
Appendix  C: Investigator Consent to Use of Personal Information  
Cerevance will collect and retain personal information of Investigator, including his or her name, 
address, and other personally identifiable information. In addition, Investigator’s personal 
information may be transferred to other parties located in countries throughout the world (e.g., the [LOCATION_008], [LOCATION_002], and Japan), including the following: 
• Cerevance, its affiliates, and licensing partners  
• Business partners assisting Cerevance, its affiliates, and licensing partners  
• Regulatory agencies and other health authorities 
• IRBs  
• Investigator’s personal information may be retained, processed, and transferred by [CONTACT_174395]: 
• Assessment of the suitability of Investigator for the study and/or other clinical studies 
• Management, monitoring, inspection, and audit of the study 
• Analysis, review, and verification of the study results 
• Safety reporting and pharmacovigilance relating to the study 
• Preparation and submission of regulatory filings, correspondence, and communications to regulatory agencies r elating to the study 
• Preparation and submission of regulatory filings, correspondence, and communications to regulatory agencies relating to other medications used in other clinical studies that may contain the same chemical compound present in the study m edication  
• Inspections and investigations by [CONTACT_63210] 
• Self-inspection and internal audit within Cerevance, its affiliates, and licensing partners  
• Archiving and audit of study records 
• Posting I nvestigator site contact [CONTACT_35865], study details and results on publicly accessible 
clinical trial registries, databases, and websites  
• Investigator’s personal information may be transferred to other countries that do not have data protection laws that offer the same level of protection as data protection laws in Investigator’s own country. 
• Investigator acknowledges and consents to the use of his or her personal information by [CONTACT_174396]. 
 
DocuSign Envelope ID: 74E08A92-D544-45CF-B868-751DF4A7415A
CVN424-102; CA38736; 16.1.1 Protocol and Protocol Amendments
Page 69 of 70
Si g nat ure Pa ge f or V V- 1 2 8 4 3 2 v 1. 0 
Si g nat ure Pa ge f or V V- 1 2 8 4 3 2 v 1. 0 Reas o n f or si g ni n g: A p pr o ve Na me: M D 
R ole: Pri nci pal I n vesti gat or 
Date of si g nat ure: 0 8- Se p- 2 0 2 2 1 7: 2 3: 1 7 G M T + 0 0 0 0 C A 3 8 7 3 6 Cere va nce Pr ot oc ol Si g nat ure Pa ge ( PI), 3 0 A u g 2 0 2 2 
Va ult D oc #: V V- 1 2 8 4 3 2 | Va ult D oc Versi o n: 1. 0 
C V N 4 2 4- 1 0 2; C A 3 8 7 3 6; 1 6. 1. 1 Pr ot oc ol a n d Pr ot oc ol A me n d me nts Pa ge 7 0 of 7 0 P P D 